Navidea Biopharmaceuticals (NAVB) 10-K 28 Mar 22 2021 FY Annual report Financial data

Document And Entity Information

Document And Entity Information - USD ($)	12 Months Ended
	Dec. 31, 2021	Mar. 18, 2022	Jun. 30, 2021
Document Information [Line Items]
Entity Central Index Key	0000810509
Entity Registrant Name	NAVIDEA BIOPHARMACEUTICALS, INC.
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Document Fiscal Period Focus	FY
Document Fiscal Year Focus	2021
Document Type	10-K
Document Annual Report	true
Document Period End Date	Dec. 31, 2021
Document Transition Report	false
Entity File Number	001-35076
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	31-1080091
Entity Address, Address Line One	4995 Bradenton Avenue, Suite 240
Entity Address, City or Town	Dublin
Entity Address, State or Province	OH
Entity Address, Postal Zip Code	43017-3552
City Area Code	614
Local Phone Number	793-7500
Title of 12(b) Security	Common Stock, par value $.001 per share
Trading Symbol	NAVB
Security Exchange Name	NYSEAMER
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
ICFR Auditor Attestation Flag	false
Entity Shell Company	false
Entity Public Float			$ 35,956,327
Entity Common Stock, Shares Outstanding		30,299,054
Auditor Name	Marcum LLP
Auditor Location	Hartford, CT
Auditor Firm ID	688

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($)	Dec. 31, 2021	Dec. 31, 2020
Current assets:
Cash and cash equivalents	$ 4,230,865	$ 2,670,495
Stock subscriptions and other receivables	92,992	2,987,319
Inventory	151,155	169,798
Prepaid expenses and other	908,273	700,716
Total current assets	5,383,285	6,528,328
Property and equipment	866,306	845,379
Less accumulated depreciation and amortization	745,816	713,217
Property and equipment, net	120,490	132,162
Right-of-use lease assets	448,940	458,280
Less accumulated amortization	320,725	208,185
Right-of-use lease assets, net	128,215	250,095
License agreements, patents and trademarks	953,424	747,863
Less accumulated amortization	167,773	127,622
License agreements, patents and trademarks, net	785,651	620,241
Other assets	227,192	227,192
Total assets	6,644,833	7,758,018
Current liabilities:
Accounts payable	1,421,317	1,161,717
Accrued liabilities and other	3,149,340	2,512,994
Notes payable	453,427	745,443
Lease liabilities, current	275,718	294,951
Total current liabilities	5,299,802	4,715,105
Lease liabilities, net of current portion	20,288	296,006
Deferred revenue	700,000	700,000
Total liabilities	6,020,090	5,711,111
Commitments and contingencies (See Note 12)
Stockholders’ equity:
Common stock; $.001 par value; 300,000,000 shares authorized; 30,279,922 and 27,149,691 shares issued and outstanding as of December 31, 2021 and 2020, respectively	221,277	218,146
Common stock subscribed; $.001 par value, 0 and 995,000 shares subscribed as of December 31, 2021 and 2020, respectively	0	995
Common stock subscriptions receivable	0	(4,975,000)
Additional paid-in capital	370,459,705	375,428,014
Accumulated deficit	(370,787,610)	(359,056,683)
Total Navidea stockholders' (deficit) equity	(106,556)	1,315,604
Noncontrolling interest	731,299	731,303
Total stockholders’ equity	624,743	2,046,907
Total liabilities and stockholders’ equity	6,644,833	7,758,018
Non-Series Preferred Stock [Member]
Stockholders’ equity:
Preferred stock	0	0
Series D Preferred Stock [Member]
Stockholders’ equity:
Preferred stock	22	0
Preferred stock. subscriptions	0	132
Series D preferred stock subscriptions receivable	0	(10,300,000)
Series E Preferred Stock [Member]
Stockholders’ equity:
Preferred stock	$ 50	$ 0

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parentheticals) - $ / shares	Dec. 31, 2021	Dec. 31, 2020
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized (in shares)	300,000,000	300,000,000
Common stock, shares issued (in shares)	30,279,922	27,149,691
Common stock, shares outstanding (in shares)	30,279,922	27,149,691
Common stock subscription, shares authorized (in shares)	0	995,000
Non-Series Preferred Stock [Member]
Preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001
Preferred stock, shares authorized (in shares)	5,000,000	5,000,000
Preferred stock, shares issued (in shares)	0	0
Preferred stock, shares outstanding (in shares)	0	0
Series D Preferred Stock [Member]
Preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001
Preferred stock, shares authorized (in shares)	150,000	150,000
Preferred stock, shares issued (in shares)	22,077	0
Preferred stock, shares outstanding (in shares)	22,077	0
Preferred stock subscriptions, subscribed (in shares)	0	103,000
Series E Preferred Stock [Member]
Preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001
Preferred stock, shares authorized (in shares)	50,000	50,000
Preferred stock, shares outstanding (in shares)	50,000	0

Consolidated Statements of Oper

Consolidated Statements of Operations - USD ($)		12 Months Ended
		Dec. 31, 2021	Dec. 31, 2020
Revenue:
Revenue from contract with customer		$ 46,000	$ 119,000
Grant and other revenue		485,898	796,288
Total revenue		531,513	915,013
Cost of revenue		0	1,048
Gross profit		531,513	913,965
Operating expenses:
Research and development		5,141,910	4,930,187
Selling, general and administrative		7,450,015	6,694,959
Total operating expenses		12,591,925	11,625,146
Loss from operations	[1]	(12,060,412)	(10,711,181)
Other income (expense):
Interest (expense) income, net		(6,361)	11,344
Gain on extinguishment of debt		366,000	0
Other, net		(14,115)	(21,854)
Total other income (expense), net		345,524	(10,510)
Net loss before income taxes		(11,714,888)	(10,721,691)
Provision for income taxes		(16,043)	0
Net loss		(11,730,931)	(10,721,691)
Loss attributable to noncontrolling interest		4	0
Deemed dividend on Series C and Series D Preferred Stock beneficial conversion feature		0	(663,889)
Net loss attributable to common stockholders		$ (11,730,927)	$ (11,385,580)
Loss attributable to common stockholders per common share (basic and diluted) (in dollars per share)		$ (0.40)	$ (0.48)
Weighted average shares outstanding (in shares)		29,343,542	23,896,001
Royalty [Member]
Revenue:
Revenue from contract with customer		$ 0	$ 7,995
License [Member]
Revenue:
Revenue from contract with customer		$ 45,615	$ 110,730
[1]	Loss from operations does not reflect the allocation of certain selling, general and administrative expenses, excluding depreciation and amortization, to our individual reportable segments, other than those expenses directly incurred by Navidea Europe, Navidea UK and MT.

Consolidated Statements of Stoc

Consolidated Statements of Stockholders' Equity - USD ($)	Private Placement [Member]Preferred Stock Subscription [Member]	Private Placement [Member]Preferred Stock Subscriptions Receivable [Member]	Private Placement [Member]Additional Paid-in Capital [Member]	Private Placement [Member]Preferred Stock [Member]	Private Placement [Member]Common Stock [Member]	Private Placement [Member]Common Stock Subscription [Member]	Private Placement [Member]Common Stock Subscriptions Receivable [Member]	Private Placement [Member]Retained Earnings [Member]	Private Placement [Member]Noncontrolling Interest [Member]	Private Placement [Member]	Registered Direct Offering [Member]Preferred Stock Subscription [Member]	Registered Direct Offering [Member]Preferred Stock Subscriptions Receivable [Member]	Registered Direct Offering [Member]Additional Paid-in Capital [Member]	Registered Direct Offering [Member]Preferred Stock [Member]	Registered Direct Offering [Member]Common Stock [Member]	Registered Direct Offering [Member]Common Stock Subscription [Member]	Registered Direct Offering [Member]Common Stock Subscriptions Receivable [Member]	Registered Direct Offering [Member]Retained Earnings [Member]	Registered Direct Offering [Member]Noncontrolling Interest [Member]	Registered Direct Offering [Member]	Director Fees [Member]Preferred Stock Subscription [Member]	Director Fees [Member]Preferred Stock Subscriptions Receivable [Member]	Director Fees [Member]Additional Paid-in Capital [Member]	Director Fees [Member]Preferred Stock [Member]	Director Fees [Member]Common Stock [Member]	Director Fees [Member]Common Stock Subscription [Member]	Director Fees [Member]Common Stock Subscriptions Receivable [Member]	Director Fees [Member]Retained Earnings [Member]	Director Fees [Member]Noncontrolling Interest [Member]	Director Fees [Member]	Series C Preferred Stock [Member]Preferred Stock Subscription [Member]	Series C Preferred Stock [Member]Preferred Stock Subscriptions Receivable [Member]	Series C Preferred Stock [Member]Additional Paid-in Capital [Member]	Series C Preferred Stock [Member]Preferred Stock [Member]	Series C Preferred Stock [Member]Common Stock [Member]	Series C Preferred Stock [Member]Common Stock Subscription [Member]	Series C Preferred Stock [Member]Common Stock Subscriptions Receivable [Member]	Series C Preferred Stock [Member]Retained Earnings [Member]	Series C Preferred Stock [Member]Noncontrolling Interest [Member]	Series C Preferred Stock [Member]	Series D Preferred Stock [Member]Preferred Stock Subscription [Member]	Series D Preferred Stock [Member]Preferred Stock Subscriptions Receivable [Member]	Series D Preferred Stock [Member]Additional Paid-in Capital [Member]	Series D Preferred Stock [Member]Preferred Stock [Member]	Series D Preferred Stock [Member]Common Stock [Member]	Series D Preferred Stock [Member]Common Stock Subscription [Member]	Series D Preferred Stock [Member]Common Stock Subscriptions Receivable [Member]	Series D Preferred Stock [Member]Retained Earnings [Member]	Series D Preferred Stock [Member]Noncontrolling Interest [Member]	Series D Preferred Stock [Member]	Series E Preferred Stock [Member]Additional Paid-in Capital [Member]	Series E Preferred Stock [Member]Preferred Stock [Member]	Series E Preferred Stock [Member]	Preferred Stock Subscription [Member]	Preferred Stock Subscriptions Receivable [Member]	Additional Paid-in Capital [Member]	Preferred Stock [Member]	Common Stock [Member]	Common Stock Subscription [Member]	Common Stock Subscriptions Receivable [Member]	Retained Earnings [Member]	Noncontrolling Interest [Member]	Total
Balance (in shares) at Dec. 31, 2019																																																						0				19,234,960	902,162
Balance at Dec. 31, 2019																																																						$ 0	$ 0	$ 345,847,676		$ 210,232	$ 902	$ 0	$ (347,671,102)	$ 731,303	$ (880,989)
Issued stock in payment of services (in shares)																																																						0			0	23,810	0
Issued stock in payment of services																																																						$ 0	0	70,177	$ 0	$ 24	$ 0	0	0	0	70,201
Issued stock in payment of employee bonuses (in shares)																																																						0			0	94,159	0
Issued stock in payment of employee bonuses																																																						$ 0	0	171,428	$ 0	$ 94	$ 0	0	0	0	171,522
Issued stock (in shares)	0			0	3,280,691	(902,162)					0			0	1,647,059	0															0			420,000	0	0					0			17,750	0	0
Issued stock	$ 0	$ 0	$ 320	$ 0	$ 3,281	$ (902)	$ 0	$ 0	$ 0	$ 2,059	$ 0	$ 0	$ 1,248,353	$ 0	$ 1,647	$ 0	$ 0	$ 0	$ 0	$ 1,250,000											$ 0	$ 0	$ 4,162,758	$ 420	$ 0	$ 0	$ 0	$ 0	$ 0	$ 4,163,178	$ 0	$ 0	$ 132,089	$ 18	$ 0	$ 0	$ 0	$ 0	$ 0	$ 132,107
Issued stock	$ 0	0	(320)	$ 0	$ (3,281)	$ 902	0	0	0	(2,059)	$ 0	0	(1,248,353)	$ 0	$ (1,647)	$ 0	0	0	0	(1,250,000)											0	0	(4,162,758)	(420)	0	0	0	0	0	(4,163,178)	0	0	(132,089)	(18)	0	0	0	0	0	(132,107)
Issued restricted stock (in shares)																																																										60,000
Issued restricted stock																																																										$ 60					$ 60
Issued stock to 401(k) plan (in shares)																																																										32,651					32,651
Issued stock to 401(k) plan																																																								39,801		$ 33					$ 39,834
Issued stock upon exercise of warrants (in shares)																																																						0			0	300,595	0
Issued stock upon exercise of warrants																																																						$ 0	0	(300)	$ 0	$ 300	$ 0	0	0	0	0
Deemed dividend																															$ 0	0	466,667	$ 0	$ 0	$ 0	0	(466,667)	0	0	$ 0	0	197,223	$ 0	$ 0	$ 0	0	(197,223)	0	0
Issued stock upon conversion (in shares)																															0			(420,000)	1,425,076	0								(17,750)	827,280	0
Issued stock upon conversion																															$ 0	0	(1,005)	$ (420)	$ 1,425	$ 0	0	0	0	0			809	$ 18	$ (827)
Issued stock in payment of Series C Preferred Stock fees (in shares)																															0			0	14,205	0																		0			0	209,205	0
Issued stock in payment of Series C Preferred Stock fees																															$ 0	0	(14)	$ 0	$ 14	$ 0	0	0	0	0
Issued stock pursuant to Jubilant MOU																																																						$ 0	0	999,791	$ 0	$ 209	$ 0	0	0	0	1,000,000
Issued stock upon conversion																															$ 0	0	1,005	$ 420	$ (1,425)	$ 0	0	0	0	0			(809)	$ (18)	$ 827
Stock subscribed (in shares)	0			0	0	995,000																																			132,250			0	0	0
Stock subscribed	$ 0	0	7,014,126	$ 0	$ 0	$ 995	(4,975,000)	0	0	2,040,121																															$ 132	(10,300,000)	14,849,851	$ 0	$ 0	$ 0	0	0	0	4,549,983
Stock compensation expense																																																								230,522							230,522
Net loss																																																													(10,721,691)	0	$ (10,721,691)
Issued stock (in shares)	0			0	3,280,691	(902,162)					0			0	1,647,059	0															0			420,000	0	0					0			17,750	0	0
Issued stock	$ 0	$ 0	$ 320	$ 0	$ 3,281	$ (902)	$ 0	$ 0	$ 0	$ 2,059	$ 0	$ 0	$ 1,248,353	$ 0	$ 1,647	$ 0	$ 0	$ 0	$ 0	$ 1,250,000											$ 0	$ 0	$ 4,162,758	$ 420	$ 0	$ 0	$ 0	$ 0	$ 0	$ 4,163,178	$ 0	0	132,089	$ 18	$ 0	$ 0	$ 0	$ 0	$ 0	132,107
Issued stock upon stock option exercise (in shares)																																																															0
Balance (in shares) at Dec. 31, 2020																																																						132,250			0	27,149,691	995,000
Balance at Dec. 31, 2020																																																						$ 132	(10,300,000)	375,428,014		$ 218,146	$ 995	(4,975,000)	(359,056,683)	731,303	$ 2,046,907
Issued stock (in shares)																																									(76,827)			76,827								50,000
Issued stock																																									$ (76)	2,550,000		$ 77						2,550,001	$ 4,929,988	$ 50	$ 4,930,038
Issued stock																																									$ 76	(2,550,000)		$ (77)						(2,550,001)	(4,929,988)	$ (50)	(4,930,038)
Issued restricted stock (in shares)																																																						0			0	105,000	0
Issued restricted stock																																																						$ 0	0	0	$ 0	$ 106	$ 0	0	0	0	$ 106
Issued stock to 401(k) plan (in shares)																																																						0			0	30,018	0				30,018
Issued stock to 401(k) plan																																																						$ 0	0	76,816	$ 0	$ 30	$ 0	0	0	0	$ 76,846
Issued stock upon conversion (in shares)																																												(54,750)	2,951,509	0
Issued stock upon conversion																																											2,896	$ 55	$ (2,951)
Issued stock upon conversion																																											(2,896)	$ (55)	$ 2,951
Stock subscribed (in shares)																																									(55,423)													0			0	0	(995,000)
Stock subscribed																																									$ (56)	7,750,000	$ (5,542,245)							2,207,699				$ 0	0	(4,974,005)	$ 0	$ 0	$ (995)	4,975,000	0	0	0
Stock compensation expense																																																								471,262							471,262
Net loss																																																						$ 0	0	0	$ 0	$ 0	$ 0	0	(11,730,927)	(4)	$ (11,730,931)
Issued stock (in shares)																																									(76,827)			76,827								50,000
Issued stock																																									$ (76)	$ 2,550,000		$ 77						$ 2,550,001	$ 4,929,988	$ 50	$ 4,930,038
Issued stock upon stock option exercise (in shares)																																																										4,000					4,000
Issued stock upon stock option exercise																																																								4,236		$ 4					$ 4,240
Issued stock in lieu of cash for payment of director fees (in shares)																					0			0	53,819	0
Issued stock in lieu of cash for payment of director fees																					$ 0	$ 0	$ 85,881	$ 0	$ 54	$ 0	$ 0	$ 0	$ 0	$ 85,935
Cancelled stock to pay employee tax obligations (in shares)																																																						0			0	(14,115)	0
Cancelled stock to pay employee tax obligations																																																						$ 0	$ 0	(17,346)	$ 0	$ (14)	$ 0	$ 0	0	0	(17,360)
Balance (in shares) at Dec. 31, 2021																																																						0			72,077	30,279,922
Balance at Dec. 31, 2021																																																						$ 0		$ 370,459,705	$ 72	$ 221,277			$ (370,787,610)	$ 731,299	$ 624,743

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Cash flows from operating activities:
Net loss	$ (11,730,931)	$ (10,721,691)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization of property and equipment	36,803	33,929
Amortization of license agreements, patents and trademarks	40,151	36,464
Non-cash lease expense	121,880	120,186
Loss on disposal and abandonment of patents and equipment	98,733	5,654
Stock compensation expense	471,262	230,521
Gain on extinguishment of debt	(366,000)	0
Value of stock issued to 401(k) plan for employer matching contributions	76,846	39,834
Value of stock issued in lieu of cash in payment of director fees	85,935	0
Value of stock issued in payment of employee bonuses	0	171,522
Value of stock issued in payment for services	0	70,201
Changes in operating assets and liabilities:
Receivables	(30,675)	839,020
Inventory	18,643	(169,798)
Prepaid expenses and other assets	358,203	1,019,230
Accounts payable	259,600	49,648
Accrued and other liabilities	622,738	348,410
Lease liabilities	(294,951)	(260,532)
Deferred revenue	13,608	13,609
Net cash used in operating activities	(10,218,155)	(8,173,793)
Cash flows from investing activities:
Payments for purchases of equipment	(25,218)	(135,881)
Proceeds from sales of equipment	0	1,042
Patent and trademark costs	(304,206)	(277,989)
Net cash used in investing activities	(329,424)	(412,828)
Cash flows from financing activities:
Proceeds from issuance of preferred stock, including collection of stock subscriptions receivable	12,682,700	5,975,000
Proceeds from issuance of common stock	4,346	4,442,560
Payment of tax withholdings related to stock-based compensation	(17,360)	0
Proceeds from note payable	0	366,000
Principal payments on notes payable	(491,775)	(368,553)
Net cash provided by financing activities	12,107,949	10,209,957
Net increase in cash and cash equivalents	1,560,370	1,623,336
Cash and cash equivalents, beginning of period	2,670,495	1,047,159
Cash and cash equivalents, end of period	4,230,865	2,670,495
Preferred Stock Issuance Costs [Member]
Cash flows from financing activities:
Payment of stock issuance costs	(69,962)	(55,050)
Common Stock Issuance Costs [Member]
Cash flows from financing activities:
Payment of stock issuance costs	$ 0	$ (150,000)

Note 1 - Organization and Summa

Note 1 - Organization and Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2021
Notes to Financial Statements
Significant Accounting Policies [Text Block]	1. Organization and Summary of Significant Accounting Policies a. Organization and Nature of Operations: Navidea’s Manocept platform is predicated on the ability to specifically target the CD206 Tc99m first Tc99m none In July 2011, Tc99m In January 2015, In June 2020, b. Principles of Consolidation: c. Use of Estimates: d. Revenue Recognition: one We also earn revenues related to our licensing and distribution agreements. The consideration we are eligible to receive under our licensing and distribution agreements typically includes upfront payments, reimbursement for research and development (“R&D”) costs, milestone payments, and royalties. Each licensing and distribution agreement is unique and requires separate assessment in accordance with current accounting standards. See Note 3. e. Stock-Based Compensation: December 31, 2021, two 2002 “2002 2014 “2014 2014 may may 2014 2002 2002 no may Stock options granted under the 2002 2014 one four not ten Stock-based payments to employees and directors, including grants of stock options and restricted stock, are recognized in the statements of operations based on their estimated fair values on the date of grant, subject to an estimated forfeiture rate. The fair value of each option award with time-based vesting provisions is estimated on the date of grant using the Black-Scholes option pricing model. The determination of fair value using the Black-Scholes option pricing model is affected by our stock price as well as assumptions regarding a number of complex and subjective variables, including expected stock price volatility, risk-free interest rate, expected dividends and projected employee stock option behaviors. The fair value of each option award with market-based vesting provisions is estimated on the date of grant using a Monte Carlo simulation. The determination of fair value using a Monte Carlo simulation is affected by our stock price as well as assumptions regarding a number of complex and subjective variables, including expected stock price volatility, risk-free interest rate, expected dividends and projected employee stock option behaviors. Expected volatilities are based on the Company’s historical volatility, which management believes represents the most accurate basis for estimating expected future volatility under the current circumstances. Navidea uses historical data to estimate forfeiture rates. The expected term of stock options granted is based on the vesting period and the contractual life of the options. The risk-free rate is based on the U.S. Treasury yield in effect at the time of the grant. The assumptions used to calculate the fair value of stock option awards granted during the years ended December 31, 2021 2020 2021 2020 Expected volatility 90% - 102% 86% - 102% Weighted-average volatility 95% 92% Expected forfeiture rate 5.2% - 9.0% 7.0% - 10.5% Expected term (in years) 5.5 - 6.2 5.5 - 6.0 Risk-free rate 0.6% - 1.4% 0.4% - 1.5% Expected dividends — — The portion of the fair value of stock-based awards that is ultimately expected to vest is recognized as compensation expense over either ( 1 2 may not not 4. f. Research and Development Costs: g. Stock Subscriptions and Other Receivables: 6. h. Inventory: first first 7. i. Intangible Assets: no 2021 2020, 2021 2020, j. Leases: 2018. 12 not 11. k. Contingent Liabilities: 450, Contingencies 10 In assessing whether we should accrue a liability in our financial statements as a result of the lawsuits, we considered various factors, including the legal and factual circumstances of the cases, the trial records and post-trial rulings of the applicable courts and appellate courts, the current status of the proceedings, applicable law and the views of legal counsel. We have concluded that a loss from these cases is not not December 31, 2021. not may 12. l. Convertible Preferred Stock: 480, Distinguishing Liabilities from Equity 815, Derivatives and Hedging 470, Debt 268, Presentation in Financial Statements of Redeemable Preferred Stocks not not No. 2020 06, Accounting for Convertible Instruments and Contracts in an Entity s Own Equity January 1, 2021, 2020 06, no not not 13. m. Income Taxes: December 31, 2021 2020. Current accounting standards include guidance on the accounting for uncertainty in income taxes recognized in the financial statements. Such standards also prescribe a recognition threshold and measurement model for the financial statement recognition of a tax position taken, or expected to be taken, and provides guidance on derecognition, classification, interest and penalties, accounting in interim periods, disclosure and transition. The Company believes that the ultimate deductibility of all tax positions is highly certain, although there is uncertainty about the timing of such deductibility. As a result, no liability for uncertain tax positions was recorded as of December 31, 2021 2020 not twelve December 31, 2021, 2018 2021 14. n. Recently Adopted Accounting Standards: August 2018, No. 2018 13, Fair Value Measurement (Topic 820 Disclosure Framework Changes to the Disclosure Requirements for Fair Value Measurement 2018 13 820. 2018 13 December 15, 2019. 2018 13 not In December 2019, No. 2019 12, Income Taxes (Topic 740 2019 12 2019 12 740 2019 12 December 12, 2020, 2019 12 not In August 2020, No. 2020 06, Accounting for Convertible Instruments and Contracts in an Entity s Own Equity 2020 06 2020 06 2020 06 2020 06 December 15, 2021, December 15, 2023 2020 06 January 1, 2021 2020 06, 2020 06, no 2020 06 not o. Recently Issued Accounting Standards: May 2021, No. 2021 04, Issuer s Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options 2021 04 2021 04 2021 04 2021 04 December 15, 2021, not 2021 04 In November 2021, No. 2021 10, Disclosures by Business Entities about Government Assistance 2021 10 2021 10 1 2 3 2021 10 December 15, 2021. 2021 10 1 2 not 2021 10

Note 2 - Liquidity

Note 2 - Liquidity	12 Months Ended
	Dec. 31, 2021
Notes to Financial Statements
Substantial Doubt about Going Concern [Text Block]	2. Liquidity The Company has been engaged in litigation with Platinum-Montaur Life Sciences LLC (“Platinum-Montaur”), an affiliate of Platinum Management (NY) LLC, Platinum Partners Value Arbitrage Fund L.P., Platinum Partners Capital Opportunity Fund, Platinum Partners Liquid Opportunity Master Fund L.P., Platinum Liquid Opportunity Management (NY) LLC, and Montsant Partners LLC (collectively, “Platinum”). See Note 12. In addition, the Company is engaged in ongoing litigation with our former President and Chief Executive Officer, Dr. Goldberg. See Note 12. The Company has also been engaged in ongoing litigation with Capital Royalty Partners II L.P. (“CRG”). See Note 12. In February 2020, two first three 2020. 13. On May 6, 2020, second third 2020. 13. On August 9, 2020, Tc99m The execution of the ELDA is subject to certain conditions, including negotiation of a definitive agreement in mutually acceptable form and Jubilant’s completion of its due diligence. See Note 13. On August 30, 2020, $5.0 second 2021, second 2021. December 14, 2021, 13. On August 31, 2020, one nine 3 July 7, 2021, July 8, 2021 ( no December 31, 2021 10 not 13. On March 2, 2021, 10 none 13. Navidea has used the net proceeds from these transactions to fund its R&D programs, including continued advancement of its two 2b 3 Tc99m The Coronavirus Aid, Relief, and Economic Security Act (the “CARES Act”) was enacted on March 27, 2020. 7 May 18, 2020, February 23, 2021, 10. We do not 19 19 NAV3 32 19 19 The Company has experienced recurring net losses and has used significant cash to fund its operations. The Company has considerable discretion over the extent of development project expenditures and has the ability to curtail the related cash flows as needed. The Company also has funds remaining under outstanding grant awards, and continues working to establish new sources of funding, including collaborations, potential equity investments, and additional grant funding that can augment the balance sheet. However, based on our current working capital and our projected cash burn, management believes that there is substantial doubt about the Company’s ability to continue as a going concern for a period of one 10

Note 3 - Revenue From Contracts

Note 3 - Revenue From Contracts With Customers	12 Months Ended
	Dec. 31, 2021
Notes to Financial Statements
Revenue from Contract with Customer [Text Block]	3. Revenue from Contracts with Customers Navidea is focused on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. We manage our business based on two Tc99m Tc99m one Tc99 May 11, 2020, The Company also has an agreement in place to provide Meilleur Technologies, Inc. (“Meilleur”), a wholly-owned subsidiary of Cerveau Technologies, Inc. (“Cerveau”), worldwide rights to conduct research using NAV4694, NAV4694 Currently, the Company recognizes revenue from up-front license fees and pre-market milestones after the cash has been received from its customers and the performance obligations have been met. Payments for sales-based royalties and milestones are generally received after the related revenue has been recognized and invoiced. Normal payment terms generally range from 15 to 90 days following milestone achievement or royalty invoice, in accordance with each contract. Up-front and milestone payments received related to our license and distribution agreements in India and China are deferred until Tc99m not Tc99m not no not eight ten The transaction price of a contract is the amount of consideration to which the Company expects to be entitled in exchange for transferring promised goods or services to a customer. Transaction prices do not third not When estimating a contract’s transaction price, the Company considers all the information (historical, current, and forecasted) that is reasonably available to it and identifies possible consideration amounts. Most of the Company’s contracts with customers include both fixed and variable components of the transaction price. Under those contracts, some or all of the consideration for satisfied performance obligations is contingent on events over which the Company has no Tc99m The milestone payments have a binary outcome (that is, the Company will either receive all or none not Royalties are estimated based on the expected value method because they are based on a variable amount of sales representing a range of possible outcomes. However, when taking into account the constraint on variable consideration, the estimate of future royalties included in the transaction price is generally $0. This conclusion is based on the fact that Tc99m not no no The sublicense of NAV4694 No. 606, Revenue from Contracts with Customers 606” Up-front fees, milestones and royalties are generally non-refundable. Therefore, the Company does not During the years ended December 31, 2021 2020, December 31, 2021 2020, not The following table disaggregates the Company’s revenue from contracts with customers for the years ended December 31, 2021 2020. Years Ended December 31, 2021 2020 Royalty revenue: Tc99m tilmanocept - Europe $ — $ 7,995 License revenue: Tc99m tilmanocept - Europe $ 45,615 $ 110,730 The following economic factors affect the nature, amount, timing and uncertainty of the Company’s revenue and cash flows as indicated: Geographical Location of Customers: may may Tc99m Status of Regulatory Approval: Tc99m Tc99m Tc99m not may NAV4694 not Through December 31, 2021, not The following table summarizes the changes in contract liabilities, the current portion of which is included in accrued liabilities and other in the consolidated balance sheets, during the years ended December 31, 2021 2020. Year Ended December 31, 2021 2020 Total deferred revenue, beginning of period $ 700,000 $ 700,000 Revenue deferred related to sublicense — 160,000 Refund of deferred revenue related to sublicense — (160,000 ) Revenue recognized from satisfaction of performance obligations — — Total deferred revenue, end of period $ 700,000 $ 700,000 The Company had license revenue receivable of approximately $1,000 and $59,000 outstanding as of December 31, 2021 2020, In addition to revenue from contracts from customers, we also generate revenue from National Institutes of Health (“NIH”) grants to support various product development initiatives. The revenue recognition standard applies to revenue from contracts with customers. A customer is defined as a party that has contracted with an entity to obtain goods or services that are an output of the entity’s ongoing major or central operations in exchange for consideration. The Company’s ongoing major or central operations consist of the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. The NIH and its various institutes are responsible for biomedical and public health research and provide major biomedical research funding to non-NIH research facilities and entities such as Navidea. While the Company will directly benefit from any knowledge gained from the project, there is also a public health benefit provided, which justifies the use of public funds in the form of the grants. Based on the nature of the Company’s operations and the terms of the grant awards, Navidea does not not December 31, 2021 2020, On May 11, 2020 ( March 5, 2015 ( Tc99m Pursuant to the Termination Agreement, the parties agreed that neither owed the other any payments due under the License Agreement as of the Termination Date and that, among other things, SpePharm no six ninety fourth 2021.

Note 4 - Stock-based Compensati

Note 4 - Stock-based Compensation	12 Months Ended
	Dec. 31, 2021
Notes to Financial Statements
Share-based Payment Arrangement [Text Block]	4. Stock-Based Compensation For the years ended December 31, 2021 2020, not December 31, 2021 2020. On November 23, 2021, October 24, 2021 ( eighth may fifth thirty fourth 2021. A summary of the status of our stock options as of December 31, 2021, Year Ended December 31, 2021 Number of Options Weighted Average Exercise Price Weighted Average Remaining Contractual Life (in years) Aggregate Intrinsic Value Outstanding, January 1, 2021 549,970 $ 8.81 Granted 459,500 1.94 Exercised (4,000 ) 1.06 Canceled and forfeited (83,590 ) 4.70 Expired (2,090 ) 61.75 Outstanding, December 31, 2021 919,790 $ 5.67 6.5 $ — Exercisable, December 31, 2021 549,024 $ 8.40 4.6 $ — The weighted average grant-date fair value of options granted in 2021 2020 2021, No 2020. 2021 2020 A summary of the status of our unvested restricted stock as of December 31, 2021, Year Ended December 31, 2021 Number of Shares Weighted Average Grant-Date Fair Value Unvested, January 1, 2021 60,000 $ 2.90 Granted 105,000 1.48 Vested (70,000 ) 2.81 Unvested, December 31, 2021 95,000 $ 1.40 During 2021 2020, 2021 2020, As of December 31, 2021,

Note 5 - Loss Per Share

Note 5 - Loss Per Share	12 Months Ended
	Dec. 31, 2021
Notes to Financial Statements
Earnings Per Share [Text Block]	5. Loss Per Share Basic loss per share is calculated by dividing net loss attributable to common stockholders by the weighted-average number of common shares. Diluted loss per share reflects additional common shares that would have been outstanding if dilutive potential common shares had been issued. Potential common shares that may Diluted loss per common share for the years ended December 31, 2021 2020 The Company’s unvested stock awards contain nonforfeitable rights to dividends or dividend equivalents, whether paid or unpaid (referred to as “participating securities”). Therefore, the unvested stock awards are required to be included in the number of shares outstanding for both basic and diluted earnings per share calculations. However, due to our loss from continuing operations, 95,000 and 60,000 shares of unvested restricted stock for the years ended December 31, 2021 2020,

Note 6 - Stock Subscriptions an

Note 6 - Stock Subscriptions and Other Receivables and Concentrations of Credit Risk	12 Months Ended
	Dec. 31, 2021
Notes to Financial Statements
Loans, Notes, Trade and Other Receivables Disclosure [Text Block]	6. Stock Subscriptions and Other Receivables and Concentrations of Credit Risk Stock subscriptions and other receivables as of December 31, 2021 2020 2021 2020 Related parties $ 86,796 $ — Stock subscriptions — 2,925,000 License revenue 1,021 58,754 Grant revenue 919 1,117 Other 4,256 2,448 Total stock subscriptions and other receivables $ 92,992 $ 2,987,319 As of December 31, 2021 2020, December 31, 2021 2020, not 10

Note 7 - Inventory

Note 7 - Inventory	12 Months Ended
	Dec. 31, 2021
Notes to Financial Statements
Inventory Disclosure [Text Block]	7. Inventory The components of net inventory as of December 31, 2021 2020 December 31, 2021 December 31, 2020 Materials $ 50,000 $ 77,750 Finished goods 101,155 92,048 Total inventory $ 151,155 $ 169,798 During 2021 2020, 2021 2020,

Note 8 - Property and Equipment

Note 8 - Property and Equipment	12 Months Ended
	Dec. 31, 2021
Notes to Financial Statements
Property, Plant and Equipment Disclosure [Text Block]	8. Property and Equipment The major classes of property and equipment are presented in the following table. Useful Life (years) 2021 2020 Purchased software 3 $ 320,435 $ 320,435 Production machinery and equipment 5 214,356 214,356 Other machinery and equipment, primarily computers and research equipment 3 – 5 304,492 297,315 Leasehold improvements* Term of Lease 23,511 12,448 Furniture and fixtures 7 3,512 825 Total property and equipment $ 866,306 $ 845,379 * We amortize leasehold improvements over the term of the lease, which in all cases is shorter than the estimated useful life of the asset. During 2021 2020,

Note 9 - Accounts Payable, Accr

Note 9 - Accounts Payable, Accrued Liabilities and Other	12 Months Ended
	Dec. 31, 2021
Notes to Financial Statements
Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]	9. Accounts Payable, Accrued Liabilities and Other Accounts payable as of December 31, 2021 2020 December 31, 2021 2020 second 2021, December 31, 2021. fourth 2021, July 1, 2022. Accrued liabilities and other as of December 31, 2021 2020 2021 2020 Contracted services $ 1,913,756 $ 1,725,866 Compensation 1,194,719 755,494 Other 40,865 31,634 Total accrued liabilities and other $ 3,149,340 $ 2,512,994

Note 10 - Notes Payable

Note 10 - Notes Payable	12 Months Ended
	Dec. 31, 2021
Notes to Financial Statements
Debt Disclosure [Text Block]	10. Notes Payable First Insurance Funding In November 2019, eight July 2020. Interest expense related to the FIF note payable totaled $5,000 during the year ended December 31, 2020. IPFS Corporation In November 2020, seven June 2021. November 2021, five April 2022. Interest expense related to the IPFS notes payable totaled $6,000 and $1,000 during the years ended December 31, 2021 2020, December 31, 2021 2020, Paycheck Protection Program The CARES Act was enacted on March 27, 2020. 7 May 18, 2020, February 23, 2021, 2. Summary During the years ended December 31, 2021 2020, 2022.

Note 11 - Leases

Note 11 - Leases	12 Months Ended
	Dec. 31, 2021
Notes to Financial Statements
Lessee, Operating Leases [Text Block]	11. Leases We currently lease approximately 5,000 square feet of office space at 4995 June 2023. In addition, we currently lease approximately 25,000 square feet of office space at 5600 2021. October 2022 five not June 2017, October 2022. We currently lease office equipment at a monthly payment of approximately $100, expiring in October 2024. September 2021. Total operating lease expense was $172,000 and $198,000 for the years ended December 31, 2021 2020, The following table presents information about the amount, timing and uncertainty of cash flows arising from the Company’s operating leases as of December 31, 2021. Maturity of Lease Liabilities Operating Lease Payments 2022 $ 291,111 2023 19,699 2024 1,355 Total undiscounted operating lease payments 312,165 Less imputed interest 16,159 Present value of operating lease liabilities $ 296,006 Balance Sheet Classification Current lease liabilities $ 275,718 Noncurrent lease liabilities 20,288 Total operating lease liabilities $ 296,006 Other Information Weighted-average remaining lease term for operating leases (years) 0.9 Weighted-average discount rate for operating leases 10.96 % Cash paid for amounts included in the present value of operating lease liabilities was $344,000 and $339,000 during the years ended December 31, 2021 2020,

Note 12 - Commitments and Conti

Note 12 - Commitments and Contingencies	12 Months Ended
	Dec. 31, 2021
Notes to Financial Statements
Commitments and Contingencies Disclosure [Text Block]	12. Commitments and Contingencies We are subject to legal proceedings and claims that arise in the ordinary course of business. In accordance with ASC Topic 450, Contingencies CRG Litigation The Company has been engaged in ongoing litigation with CRG, in its capacity as a lender and as control agent for other affiliated lenders party to the CRG Loan Agreement (collectively, the “CRG Lenders”), in the District Court of Harris County, Texas (the “Texas Court”) relating to CRG’s claims of default under the terms the CRG Loan Agreement. Following a trial in December 2017, March 3, 2017. March 2017, not June 2016 $66.0 $4.1 $4.1 $7.0 On April 9, 2018, 414, 414” $4.1 $59.0 The Company has also been engaged in ongoing litigation with CRG in the Court of Common Pleas of Franklin County, Ohio (the “Ohio Court”) related to Navidea’s claims that the CRG Lenders fraudulently induced Navidea to enter into a settlement agreement and breached the terms of the same through certain actions taken by the CRG Lenders in connection with the GSA, pursuant to which Navidea agreed to pay up to $66.0 $66.0 $4.1 June 2016 $66.0 $66.0 $7.1 414 May 7, 2019, June 28, 2019. November 27, 2019, $66.0 April 9, 2018, 414 no December 5, 2019, 10th March 27, 2020, September 23, 2020. March 16, 2021, 10th November 27, 2019 not not In April 2018, $7.1 not On November 21, 2021, not May 17, 2022. not 2. Platinum Litigation In November 2017, March 3, 2017, October 31, 2018, no On November 30, 2018, January 22, 2019, September 5, 2019. November 25, 2019, not June 4, 2020, September 2, 2020, September 23, 2020 June 28, 2021. February 2022, 2. Goldberg Agreement and Litigation In August 2018, 1,175,000 November 2018, On February 11, 2019, February 19, 2019, March 1, 2019, February 20, 2019, may February 17, 2022, New York Litigation Involving Dr. Goldberg On February 20, 2019, April 26, 2019, June 13, 2019, third On December 26, 2019, third not The District Court also rejected Dr. Goldberg’s claim for wrongful termination as Chief Executive Officer of MT. In addition, the District Court found that Dr. Goldberg lacked standing to seek injunctive relief to force the removal of Dr. Claudine Bruck and Michael Rice from MT’s Board of Directors, to invalidate all actions taken by the MT Board on or after November 29, 2018 ( In addition, the District Court found Navidea’s breach of fiduciary duty claim against Dr. Goldberg for conduct occurring more than three On January 31, 2020, April 1, 2020, On January 27, 2020, July 9, 2020, 1 2 3 4 On August 24, 2020, not third not On May 27, 2021, 1 2 3 not 4 not third 5 6 not On August 6, 2021, June 23, 2021 ( October 14, 2021, March 7, 2022, September 1, 2020. April 8, 2022. Fact discovery and expert discovery in the New York Action have been completed. The Company has moved to disqualify Dr. Goldberg’s damages expert and briefing in the District Court on that issue will be concluded on April 1, 2022. Delaware Litigation Involving Dr. Goldberg On February 20, 2019, June 12, 2019, not May 23, 2019 On June 23, 2021, not not December 9, 2021, 2. NYSE American Continued Listing Standards On January 28, 2022, not not 1003 $6.0 five September 30, 2021, five December 31, 2020. We submitted a plan to the NYSE American on February 28, 2022 July 28, 2023. not not may no

Note 13 - Equity Instruments

Note 13 - Equity Instruments	12 Months Ended
	Dec. 31, 2021
Notes to Financial Statements
Stockholders' Equity Note Disclosure [Text Block]	13. Equity Instruments a. Preferred Stock and Common Stock: December 2019, 2019 January 2020. In February 2020, two $3.4 2020. On May 6, 2020, one November 6, 2020, not not 2020. 420,000 December 31, 2020. 2020. On August 9, 2020, Tc99m 2. On August 30, 2020, forty-five 45 no ninety 90 $5.00 five 713 no not ninety 90 not $25.0 ninety 90 no 4.99% 2020. December 31, 2020. second 2021, second 2021. December 14, 2021, 2. On August 31, 2020, one nine may not not In the event of the liquidation or dissolution of the Company, after payment of the debts and other liabilities of the Company, the holders of Series D Preferred Stock then outstanding shall be entitled to receive, out of the assets of the Company and before any payment may x Of the $15.0 2020. 17,750 2020. 2020. January 1, 2021 March 26, 2021, 2020 10 January 1, 2021 March 26, 2021. December 31, 2020. Through July 7, 2021, December 31, 2021. 2020, 2021. July 8, 2021, 22,077 no December 31, 2021. December 31, 2021 December 31, 2021, 2. On March 2, 2021, Under the Series E Preferred Stock Purchase Agreement, Mr. Scott was granted a right of first no 33.33% 13 1934, not third not no no may December 31, 2021. In connection with the private placement, the Company entered into a registration rights agreement (the “Registration Rights Agreement”), pursuant to which, among other things, the Company prepared and filed with the Securities and Exchange Commission (the “SEC”) a registration statement on Form S- 1 20% 13 144 not 1933, not may not Except with respect to transactions which may no one may not one 2. Navidea has used the net proceeds from these transactions to fund its R&D programs, including continued advancement of its two 2b 3 Tc99m 2. During the years ended December 31, 2021 2020, 401 During the year ended December 31, 2020, 2019 December 31, 2021. b. Stock Warrants: December 31, 2021, The following table summarizes information about our outstanding warrants as of December 31, 2021. Exercise Price Number of Warrants Expiration Date Series HH $ 49.80 15,060 6/25/2023 Series LL 0.20 218,264 8/20/2035 Series NN 30.00 550,000 3/3/2022 Series OO 0.9375 189,000 6/13/2024 Total warrants $ 17.97 * 972,324 * Weighted average exercise price. In addition, 300 warrants to purchase MT Common Stock at $2,000 per share expired in March 2020. c. Common Stock Reserved: December 31, 2021, July 1, 2022. 11.

Note 14- Income Taxes

Note 14- Income Taxes	12 Months Ended
	Dec. 31, 2021
Notes to Financial Statements
Income Tax Disclosure [Text Block]	14. Income Taxes As of December 31, 2021 2020, As of December 31, 2021 2020 Deferred tax assets: Net operating loss carryforwards $ 36,793,074 $ 34,365,098 R&D credit carryforwards 9,501,299 9,301,709 Stock compensation 481,098 419,654 Intangibles 567,213 616,926 Disallowed interest expense 851,247 852,338 Temporary differences 305,974 267,312 Deferred tax assets before valuation allowance 48,499,905 45,823,037 Valuation allowance (48,499,905 ) (45,823,037 ) Net deferred tax assets $ — $ — Current accounting standards require a valuation allowance against DTAs if, based on the weight of available evidence, it is more likely than not may not December 31, 2021 2020. In assessing the realizability of DTAs, management considers whether it is more likely than not not not not December 31, 2021. The Tax Cuts and Jobs Act (the “Tax Act”) was signed into law on December 22, 2017. 35% January 1, 2018. December 31, 2018. 2018, 2019 2020. may 2018 2020, 50% 2018, 2019 2020 2021. March 27, 2020 June 2020. As of December 31, 2021 2020, December 31, 2021, not December 31, 2017, 2016 09 As of December 31, 2021 2020, 2032. As of December 31, 2021 2020, There were no 2021 2020. 2021 2020, The details of our U.S. net operating loss and federal R&D credit carryforward amounts and expiration dates are summarized in the following table. As of December 31, 2021 Generated Expiration U.S. Net Operating Loss Carryforwards U.S. R&D Credit Carryforwards 2001 2021 $ — $ 39,128 2002 2022 — 5,350 2003 2023 — 2,905 2004 2024 — 22,861 2005 2025 — 218,332 2006 2026 — 365,541 2007 2027 — 342,898 2008 2028 — 531,539 2009 2029 — 596,843 2010 2030 — 1,094,449 2011 2031 — 1,950,744 2012 2032 18,898,490 468,008 2013 2033 37,450,522 681,772 2014 2034 34,088,874 816,116 2015 2035 25,073,846 492,732 2016 2036 15,581,209 262,257 2017 2037 — 387,892 2018 N/A — 197,547 2019 N/A 11,245,808 213,065 2020 N/A 11,018,478 222,842 2021 N/A 10,746,123 238,717 Total carryforwards $ 164,103,350 $ 9,112,411 Under Sections 382 383 1986, may 382 December 31, 2021 382 not Reconciliations between the statutory federal income tax rate and our effective tax rate for continuing operations are presented in the following table. 2021 2020 Amount % Amount % Benefit at statutory rate $ (2,460,126 ) (21.0 )% $ (2,390,972 ) (21.0 )% Adjustments to valuation allowance 2,676,868 22.9 % 2,521,625 22.1 % Adjustments to R&D credit carryforwards (199,589 ) (1.7 )% (151,129 ) (1.3 )% Permanent items and other (1,110 ) (0.1 )% 20,476 0.2 % Provision (benefit) per financial statements $ 16,043 $ —

Note 15- Segments

Note 15- Segments	12 Months Ended
	Dec. 31, 2021
Notes to Financial Statements
Segment Reporting Disclosure [Text Block]	15. Segments We report information about our operating segments using the “management approach” in accordance with current accounting standards. This information is based on the way management organizes and reports the segments within the enterprise for making operating decisions and assessing performance. Our reportable segments are identified based on differences in products, services and markets served. There were no inter-segment sales. We manage our business based on two Tc99m The information in the following tables is derived directly from each reportable segment’s financial reporting. Year Ended December 31, 2021 Diagnostics Therapeutics Corporate Total Royalty revenue $ — $ — $ — $ — License revenue 45,615 — — 45,615 Grant and other revenue 485,898 — — 485,898 Total revenue 531,513 — — 531,513 Research and development expenses, excluding depreciation and amortization 4,488,177 653,733 — 5,141,910 Selling, general and administrative expenses, excluding depreciation and amortization (1) — 4,438 7,368,623 7,373,061 Depreciation and amortization (2) 24,162 — 52,792 76,954 Loss from operations (3) (3,980,826 ) (658,171 ) (7,421,415 ) (12,060,412 ) Other income (4) — — 345,524 345,524 Provision for income taxes (5,452 ) (901 ) (9,690 ) (16,043 ) Net loss (3,986,278 ) (659,072 ) (7,085,581 ) (11,730,931 ) Total assets, net of depreciation and amortization: United States $ 107,931 $ — $ 6,326,031 $ 6,433,962 International 210,281 — 590 210,871 Capital expenditures — — 25,218 25,218 Year Ended December 31, 2020 Diagnostics Therapeutics Corporate Total Royalty revenue $ 7,995 $ — $ — $ 7,995 License revenue 110,730 — — 110,730 Grant and other revenue 482,221 314,067 — 796,288 Total revenue 600,946 314,067 — 915,013 Cost of revenue 1,048 — — 1,048 Research and development expenses 4,593,459 336,728 — 4,930,187 Selling, general and administrative expenses, excluding depreciation and amortization (1) 299,959 800 6,323,807 6,624,566 Depreciation and amortization (2) 10,068 — 60,325 70,393 Loss from operations (3) (4,303,588 ) (23,461 ) (6,384,132 ) (10,711,181 ) Other expense (4) — — (10,510 ) (10,510 ) Net loss (4,303,588 ) (23,461 ) (6,394,642 ) (10,721,691 ) Total assets, net of depreciation and amortization: United States $ 139,121 $ — $ 7,416,106 $ 7,555,227 International 202,791 — — 202,791 Capital expenditures 120,810 — 15,071 135,881 ( 1 General and administrative expenses, excluding depreciation and amortization, represent costs that relate to the general administration of the Company and as such are not ( 2 Depreciation and amortization are reflected in selling, general and administrative expenses ($76,954 and $70,393 for the years ended December 31, 2021 2020, ( 3 Loss from operations does not ( 4 Amounts consist primarily of gain on extinguishment of debt, interest income and interest expense, which are not

Note 16 - Material Agreements

Note 16 - Material Agreements	12 Months Ended
	Dec. 31, 2021
Notes to Financial Statements
Significant Agreements Disclosure [Text Block]	16. Material Agreements a) Research and Development Agreements: January 2002, Tc99m July 2014, third In connection with the sale of the rights to sell Tc99m 414, Tc99m 414 414 414 Tc99m Tc99m 2021 2020, 2021 2020, In July 2014, Tc99m third may 2021 2020, b) Separation Agreement: July 27, 2020 October 24, 2021, November 23, 2021, October 24, 2021 ( eighth first 12 may fifth thirty one twenty-two one two may

Note 17 - Employee Benefit Plan

Note 17 - Employee Benefit Plan	12 Months Ended
	Dec. 31, 2021
Notes to Financial Statements
Compensation and Employee Benefit Plans [Text Block]	17. Employee Benefit Plan We maintain an employee benefit plan under Section 401 “401 401 may, not 401 January 1, 2021, 401 401 401 2021 2020,

Note 18 - Supplemental Disclosu

Note 18 - Supplemental Disclosure for Statements of Cash Flows	12 Months Ended
	Dec. 31, 2021
Notes to Financial Statements
Cash Flow, Supplemental Disclosures [Text Block]	18. Supplemental Disclosure for Statements of Cash Flows We paid interest aggregating $9,000 and $6,000 in 2021 2020, February 2020, 2020, 2019 2021 2020, 401 November 2021, November 2020, 2020, 2020, 2020,

Note 19 - Subsequent Events

Note 19 - Subsequent Events	12 Months Ended
	Dec. 31, 2021
Notes to Financial Statements
Subsequent Events [Text Block]	19. Subsequent Events The Company has evaluated events and transactions subsequent to December 31, 2021 10

Significant Accounting Policies

Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2021
Accounting Policies [Abstract]
Nature of Operations [Policy Text Block]	a. Organization and Nature of Operations: Navidea’s Manocept platform is predicated on the ability to specifically target the CD206 Tc99m first Tc99m none In July 2011, Tc99m In January 2015, In June 2020,
Consolidation, Policy [Policy Text Block]	b. Principles of Consolidation:
Use of Estimates, Policy [Policy Text Block]	c. Use of Estimates:
Revenue [Policy Text Block]	d. Revenue Recognition: one We also earn revenues related to our licensing and distribution agreements. The consideration we are eligible to receive under our licensing and distribution agreements typically includes upfront payments, reimbursement for research and development (“R&D”) costs, milestone payments, and royalties. Each licensing and distribution agreement is unique and requires separate assessment in accordance with current accounting standards. See Note 3.
Share-based Payment Arrangement [Policy Text Block]	e. Stock-Based Compensation: December 31, 2021, two 2002 “2002 2014 “2014 2014 may may 2014 2002 2002 no may Stock options granted under the 2002 2014 one four not ten Stock-based payments to employees and directors, including grants of stock options and restricted stock, are recognized in the statements of operations based on their estimated fair values on the date of grant, subject to an estimated forfeiture rate. The fair value of each option award with time-based vesting provisions is estimated on the date of grant using the Black-Scholes option pricing model. The determination of fair value using the Black-Scholes option pricing model is affected by our stock price as well as assumptions regarding a number of complex and subjective variables, including expected stock price volatility, risk-free interest rate, expected dividends and projected employee stock option behaviors. The fair value of each option award with market-based vesting provisions is estimated on the date of grant using a Monte Carlo simulation. The determination of fair value using a Monte Carlo simulation is affected by our stock price as well as assumptions regarding a number of complex and subjective variables, including expected stock price volatility, risk-free interest rate, expected dividends and projected employee stock option behaviors. Expected volatilities are based on the Company’s historical volatility, which management believes represents the most accurate basis for estimating expected future volatility under the current circumstances. Navidea uses historical data to estimate forfeiture rates. The expected term of stock options granted is based on the vesting period and the contractual life of the options. The risk-free rate is based on the U.S. Treasury yield in effect at the time of the grant. The assumptions used to calculate the fair value of stock option awards granted during the years ended December 31, 2021 2020 2021 2020 Expected volatility 90% - 102% 86% - 102% Weighted-average volatility 95% 92% Expected forfeiture rate 5.2% - 9.0% 7.0% - 10.5% Expected term (in years) 5.5 - 6.2 5.5 - 6.0 Risk-free rate 0.6% - 1.4% 0.4% - 1.5% Expected dividends — — The portion of the fair value of stock-based awards that is ultimately expected to vest is recognized as compensation expense over either ( 1 2 may not not 4.
Research and Development Expense, Policy [Policy Text Block]	f. Research and Development Costs:
Receivable [Policy Text Block]	g. Stock Subscriptions and Other Receivables: 6.
Inventory, Policy [Policy Text Block]	h. Inventory: first first 7.
Intangible Assets, Finite-Lived, Policy [Policy Text Block]	i. Intangible Assets: no 2021 2020, 2021 2020,
Lessee, Leases [Policy Text Block]	j. Leases: 2018. 12 not 11.
Commitments and Contingencies, Policy [Policy Text Block]	k. Contingent Liabilities: 450, Contingencies 10 In assessing whether we should accrue a liability in our financial statements as a result of the lawsuits, we considered various factors, including the legal and factual circumstances of the cases, the trial records and post-trial rulings of the applicable courts and appellate courts, the current status of the proceedings, applicable law and the views of legal counsel. We have concluded that a loss from these cases is not not December 31, 2021. not may 12.
Stockholders' Equity Note, Redeemable Preferred Stock, Issue, Policy [Policy Text Block]	l. Convertible Preferred Stock: 480, Distinguishing Liabilities from Equity 815, Derivatives and Hedging 470, Debt 268, Presentation in Financial Statements of Redeemable Preferred Stocks not not No. 2020 06, Accounting for Convertible Instruments and Contracts in an Entity s Own Equity January 1, 2021, 2020 06, no not not 13.
Income Tax, Policy [Policy Text Block]	m. Income Taxes: December 31, 2021 2020. Current accounting standards include guidance on the accounting for uncertainty in income taxes recognized in the financial statements. Such standards also prescribe a recognition threshold and measurement model for the financial statement recognition of a tax position taken, or expected to be taken, and provides guidance on derecognition, classification, interest and penalties, accounting in interim periods, disclosure and transition. The Company believes that the ultimate deductibility of all tax positions is highly certain, although there is uncertainty about the timing of such deductibility. As a result, no liability for uncertain tax positions was recorded as of December 31, 2021 2020 not twelve December 31, 2021, 2018 2021 14.
New Accounting Pronouncements, Policy [Policy Text Block]	n. Recently Adopted Accounting Standards: August 2018, No. 2018 13, Fair Value Measurement (Topic 820 Disclosure Framework Changes to the Disclosure Requirements for Fair Value Measurement 2018 13 820. 2018 13 December 15, 2019. 2018 13 not In December 2019, No. 2019 12, Income Taxes (Topic 740 2019 12 2019 12 740 2019 12 December 12, 2020, 2019 12 not In August 2020, No. 2020 06, Accounting for Convertible Instruments and Contracts in an Entity s Own Equity 2020 06 2020 06 2020 06 2020 06 December 15, 2021, December 15, 2023 2020 06 January 1, 2021 2020 06, 2020 06, no 2020 06 not o. Recently Issued Accounting Standards: May 2021, No. 2021 04, Issuer s Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options 2021 04 2021 04 2021 04 2021 04 December 15, 2021, not 2021 04 In November 2021, No. 2021 10, Disclosures by Business Entities about Government Assistance 2021 10 2021 10 1 2 3 2021 10 December 15, 2021. 2021 10 1 2 not 2021 10

Note 1 - Organization and Sum_2

Note 1 - Organization and Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2021
Notes Tables
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]	2021 2020 Expected volatility 90% - 102% 86% - 102% Weighted-average volatility 95% 92% Expected forfeiture rate 5.2% - 9.0% 7.0% - 10.5% Expected term (in years) 5.5 - 6.2 5.5 - 6.0 Risk-free rate 0.6% - 1.4% 0.4% - 1.5% Expected dividends — —

Note 3 - Revenue From Contrac_2

Note 3 - Revenue From Contracts With Customers (Tables)	12 Months Ended
	Dec. 31, 2021
Notes Tables
Disaggregation of Revenue [Table Text Block]	Years Ended December 31, 2021 2020 Royalty revenue: Tc99m tilmanocept - Europe $ — $ 7,995 License revenue: Tc99m tilmanocept - Europe $ 45,615 $ 110,730
Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]	Year Ended December 31, 2021 2020 Total deferred revenue, beginning of period $ 700,000 $ 700,000 Revenue deferred related to sublicense — 160,000 Refund of deferred revenue related to sublicense — (160,000 ) Revenue recognized from satisfaction of performance obligations — — Total deferred revenue, end of period $ 700,000 $ 700,000

Note 4 - Stock-based Compensa_2

Note 4 - Stock-based Compensation (Tables)	12 Months Ended
	Dec. 31, 2021
Notes Tables
Share-based Payment Arrangement, Option, Activity [Table Text Block]	Year Ended December 31, 2021 Number of Options Weighted Average Exercise Price Weighted Average Remaining Contractual Life (in years) Aggregate Intrinsic Value Outstanding, January 1, 2021 549,970 $ 8.81 Granted 459,500 1.94 Exercised (4,000 ) 1.06 Canceled and forfeited (83,590 ) 4.70 Expired (2,090 ) 61.75 Outstanding, December 31, 2021 919,790 $ 5.67 6.5 $ — Exercisable, December 31, 2021 549,024 $ 8.40 4.6 $ —
Schedule of Nonvested Restricted Stock Units Activity [Table Text Block]	Year Ended December 31, 2021 Number of Shares Weighted Average Grant-Date Fair Value Unvested, January 1, 2021 60,000 $ 2.90 Granted 105,000 1.48 Vested (70,000 ) 2.81 Unvested, December 31, 2021 95,000 $ 1.40

Note 6 - Stock Subscriptions _2

Note 6 - Stock Subscriptions and Other Receivables and Concentrations of Credit Risk (Tables)	12 Months Ended
	Dec. 31, 2021
Notes Tables
Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block]	2021 2020 Related parties $ 86,796 $ — Stock subscriptions — 2,925,000 License revenue 1,021 58,754 Grant revenue 919 1,117 Other 4,256 2,448 Total stock subscriptions and other receivables $ 92,992 $ 2,987,319

Note 7 - Inventory (Tables)

Note 7 - Inventory (Tables)	12 Months Ended
	Dec. 31, 2021
Notes Tables
Schedule of Inventory, Current [Table Text Block]	December 31, 2021 December 31, 2020 Materials $ 50,000 $ 77,750 Finished goods 101,155 92,048 Total inventory $ 151,155 $ 169,798

Note 8 - Property and Equipme_2

Note 8 - Property and Equipment (Tables)	12 Months Ended
	Dec. 31, 2021
Notes Tables
Property, Plant and Equipment [Table Text Block]	Useful Life (years) 2021 2020 Purchased software 3 $ 320,435 $ 320,435 Production machinery and equipment 5 214,356 214,356 Other machinery and equipment, primarily computers and research equipment 3 – 5 304,492 297,315 Leasehold improvements* Term of Lease 23,511 12,448 Furniture and fixtures 7 3,512 825 Total property and equipment $ 866,306 $ 845,379

Note 9 - Accounts Payable, Ac_2

Note 9 - Accounts Payable, Accrued Liabilities and Other (Tables)	12 Months Ended
	Dec. 31, 2021
Notes Tables
Schedule of Accrued Liabilities [Table Text Block]	2021 2020 Contracted services $ 1,913,756 $ 1,725,866 Compensation 1,194,719 755,494 Other 40,865 31,634 Total accrued liabilities and other $ 3,149,340 $ 2,512,994

Note 11 - Leases (Tables)

Note 11 - Leases (Tables)	12 Months Ended
	Dec. 31, 2021
Notes Tables
Lessee, Operating Lease, Liability, Maturity [Table Text Block]	Maturity of Lease Liabilities Operating Lease Payments 2022 $ 291,111 2023 19,699 2024 1,355 Total undiscounted operating lease payments 312,165 Less imputed interest 16,159 Present value of operating lease liabilities $ 296,006
Lessee, Operating Lease, Assets and Liabilities [Table Text Block]	Balance Sheet Classification Current lease liabilities $ 275,718 Noncurrent lease liabilities 20,288 Total operating lease liabilities $ 296,006
Lessee, Leases, Other Information [Table Text Block]	Other Information Weighted-average remaining lease term for operating leases (years) 0.9 Weighted-average discount rate for operating leases 10.96 %

Note 13 - Equity Instruments (T

Note 13 - Equity Instruments (Tables)	12 Months Ended
	Dec. 31, 2021
Notes Tables
Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]	Exercise Price Number of Warrants Expiration Date Series HH $ 49.80 15,060 6/25/2023 Series LL 0.20 218,264 8/20/2035 Series NN 30.00 550,000 3/3/2022 Series OO 0.9375 189,000 6/13/2024 Total warrants $ 17.97 * 972,324

Note 14- Income Taxes (Tables)

Note 14- Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2021
Notes Tables
Schedule of Deferred Tax Assets and Liabilities [Table Text Block]	As of December 31, 2021 2020 Deferred tax assets: Net operating loss carryforwards $ 36,793,074 $ 34,365,098 R&D credit carryforwards 9,501,299 9,301,709 Stock compensation 481,098 419,654 Intangibles 567,213 616,926 Disallowed interest expense 851,247 852,338 Temporary differences 305,974 267,312 Deferred tax assets before valuation allowance 48,499,905 45,823,037 Valuation allowance (48,499,905 ) (45,823,037 ) Net deferred tax assets $ — $ —
Summary of Tax Credit Carryforwards [Table Text Block]	As of December 31, 2021 Generated Expiration U.S. Net Operating Loss Carryforwards U.S. R&D Credit Carryforwards 2001 2021 $ — $ 39,128 2002 2022 — 5,350 2003 2023 — 2,905 2004 2024 — 22,861 2005 2025 — 218,332 2006 2026 — 365,541 2007 2027 — 342,898 2008 2028 — 531,539 2009 2029 — 596,843 2010 2030 — 1,094,449 2011 2031 — 1,950,744 2012 2032 18,898,490 468,008 2013 2033 37,450,522 681,772 2014 2034 34,088,874 816,116 2015 2035 25,073,846 492,732 2016 2036 15,581,209 262,257 2017 2037 — 387,892 2018 N/A — 197,547 2019 N/A 11,245,808 213,065 2020 N/A 11,018,478 222,842 2021 N/A 10,746,123 238,717 Total carryforwards $ 164,103,350 $ 9,112,411
Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]	2021 2020 Amount % Amount % Benefit at statutory rate $ (2,460,126 ) (21.0 )% $ (2,390,972 ) (21.0 )% Adjustments to valuation allowance 2,676,868 22.9 % 2,521,625 22.1 % Adjustments to R&D credit carryforwards (199,589 ) (1.7 )% (151,129 ) (1.3 )% Permanent items and other (1,110 ) (0.1 )% 20,476 0.2 % Provision (benefit) per financial statements $ 16,043 $ —

Note 15- Segments (Tables)

Note 15- Segments (Tables)	12 Months Ended
	Dec. 31, 2021
Notes Tables
Schedule of Segment Reporting Information, by Segment [Table Text Block]	Year Ended December 31, 2021 Diagnostics Therapeutics Corporate Total Royalty revenue $ — $ — $ — $ — License revenue 45,615 — — 45,615 Grant and other revenue 485,898 — — 485,898 Total revenue 531,513 — — 531,513 Research and development expenses, excluding depreciation and amortization 4,488,177 653,733 — 5,141,910 Selling, general and administrative expenses, excluding depreciation and amortization (1) — 4,438 7,368,623 7,373,061 Depreciation and amortization (2) 24,162 — 52,792 76,954 Loss from operations (3) (3,980,826 ) (658,171 ) (7,421,415 ) (12,060,412 ) Other income (4) — — 345,524 345,524 Provision for income taxes (5,452 ) (901 ) (9,690 ) (16,043 ) Net loss (3,986,278 ) (659,072 ) (7,085,581 ) (11,730,931 ) Total assets, net of depreciation and amortization: United States $ 107,931 $ — $ 6,326,031 $ 6,433,962 International 210,281 — 590 210,871 Capital expenditures — — 25,218 25,218 Year Ended December 31, 2020 Diagnostics Therapeutics Corporate Total Royalty revenue $ 7,995 $ — $ — $ 7,995 License revenue 110,730 — — 110,730 Grant and other revenue 482,221 314,067 — 796,288 Total revenue 600,946 314,067 — 915,013 Cost of revenue 1,048 — — 1,048 Research and development expenses 4,593,459 336,728 — 4,930,187 Selling, general and administrative expenses, excluding depreciation and amortization (1) 299,959 800 6,323,807 6,624,566 Depreciation and amortization (2) 10,068 — 60,325 70,393 Loss from operations (3) (4,303,588 ) (23,461 ) (6,384,132 ) (10,711,181 ) Other expense (4) — — (10,510 ) (10,510 ) Net loss (4,303,588 ) (23,461 ) (6,394,642 ) (10,721,691 ) Total assets, net of depreciation and amortization: United States $ 139,121 $ — $ 7,416,106 $ 7,555,227 International 202,791 — — 202,791 Capital expenditures 120,810 — 15,071 135,881

Note 1 - Organization and Sum_3

Note 1 - Organization and Summary of Significant Accounting Policies (Details Textual) - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Patent and Trademark Costs	$ 304,000	$ 278,000
Previously Capitalized Patent Costs Abandoned	99,000	9,000
Estimated Litigation Liability	0
Unrecognized Tax Benefits, Ending Balance	$ 0	$ 0
Minimum [Member]
Finite-Lived Intangible Asset, Useful Life (Year)	5 years
Maximum [Member]
Finite-Lived Intangible Asset, Useful Life (Year)	15 years
The 2014 Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized (in shares)	1,750,000
The 2014 Plan [Member] | Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period (Year)	1 year
The 2014 Plan [Member] | Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period (Year)	4 years
The 2002 and 2014 Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period (Year)	10 years
The 2002 and 2014 Plan [Member] | Grantee Status, Former Employee [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period (Year)	90 days
Navidea Biopharmaceuticals Limited [Member]
Noncontrolling Interest, Ownership Percentage by Parent	100.00%
Macrophage Therapeutics [Member]
Noncontrolling Interest, Ownership Percentage by Parent	99.90%
Navidea Europe [Member]
Noncontrolling Interest, Ownership Percentage by Parent	100.00%

Note 1 - Organization and Sum_4

Note 1 - Organization and Summary of Significant Accounting Policies - Assumptions Used to Calculate Fair Value of Stock Option Awards Granted (Details)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Expected volatility, minimum	90.00%	86.00%
Expected volatility, maximum	102.00%	102.00%
Weighted-average volatility	95.00%	92.00%
Risk-free rate, minimum	0.60%	0.40%
Risk-free rate, maximum	1.40%	1.50%
Expected dividends	0.00%	0.00%
Minimum [Member]
Expected forfeiture rate	5.20%
Expected forfeiture rate		7.00%
Expected term (Year)	5 years 6 months	5 years 6 months
Maximum [Member]
Expected forfeiture rate	9.00%
Expected forfeiture rate		10.50%
Expected term (Year)	6 years 2 months 12 days	6 years

Note 2 - Liquidity (Details Tex

Note 2 - Liquidity (Details Textual) - USD ($)	Mar. 25, 2022	Jul. 08, 2021	Mar. 02, 2021	Feb. 23, 2021	Aug. 31, 2020	Aug. 30, 2020	Aug. 09, 2020	May 18, 2020	May 06, 2020	Feb. 29, 2020	Jan. 31, 2020	Dec. 31, 2019	Jan. 31, 2020	Mar. 25, 2021	Sep. 30, 2020	Sep. 30, 2020	Jul. 07, 2021	Dec. 31, 2021	Dec. 31, 2020	Jun. 30, 2021
Proceeds from Issuance of Common Stock																		$ 4,346	$ 4,442,560
Proceeds from Issuance of Preferred Stock and Preference Stock																		$ 12,682,700	$ 5,975,000
Common Stock, Par or Stated Value Per Share (in dollars per share)																		$ 0.001	$ 0.001
Common Stock, Share Subscribed but Unissued, Subscriptions Receivable																		$ 0	$ 4,975,000
Proceeds from Notes Payable, Total																		0	366,000
Gain (Loss) on Extinguishment of Debt, Total																		366,000	0
Paycheck Protection Program CARES Act [Member]
Proceeds from Notes Payable, Total								$ 366,000
Gain (Loss) on Extinguishment of Debt, Total				$ 366,000
Private Placement [Member]
Stock Issued During Period, Shares, New Issues (in shares)													2,100,000
Proceeds from Issuance of Common Stock											$ 812,000	$ 1,100,000	$ 1,900,000
Stock Issued During Period, Value, New Issues																			2,059
Series C Preferred Stock [Member]
Stock Issued During Period, Value, New Issues																			$ 4,163,178
Conversion of Stock, Shares Converted (in shares)																420,000			420,000
Series D Preferred Stock [Member]
Stock Issued During Period, Value, New Issues																		$ 2,550,001	$ 132,107
Preferred Stock, Shares Outstanding, Ending Balance (in shares)																		22,077	0
Conversion of Stock, Shares Converted (in shares)																			17,750
Series D Preferred Stock [Member] | Subsequent Event [Member]
Preferred Stock, Shares Outstanding, Ending Balance (in shares)	22,077
Series E Preferred Stock [Member]
Stock Issued During Period, Value, New Issues																		$ 4,930,038
Preferred Stock, Shares Outstanding, Ending Balance (in shares)																		50,000	0
Series E Preferred Stock [Member] | Subsequent Event [Member]
Conversion of Stock, Shares Converted (in shares)	0
Keystone Capital Partners, LLC [Member] | Series C Preferred Stock [Member]
Stock Issued During Period, Shares, New Issues (in shares)									420,000										420,000
Proceeds from Issuance of Common Stock																			$ 4.2
Stock Issued During Period, Value, New Issues									$ 4,200,000
Proceeds from Issuance of Preferred Stock and Preference Stock															$ 4,200,000
Keystone Capital Partners, LLC [Member] | Series D Preferred Stock [Member]
Stock Issued During Period, Shares, New Issues (in shares)		22,077			150,000									29,250			72,500	76,827	17,750
Stock Issued During Period, Value, New Issues		$ 2,200,000			$ 15,000,000												$ 7,250,000	$ 7,700,000
Proceeds from Issuance of Preferred Stock and Preference Stock														$ 2,900,000					$ 1,800,000
Stock Purchase Agreement, Shares Remaining (in shares)																		77,500
Convertible Preferred Stock, Shares Issued upon Conversion (in shares)					5,147,000
Preferred Stock, Shares Outstanding, Ending Balance (in shares)																		22,077
Keystone Capital Partners, LLC [Member] | Series D Preferred Stock [Member] | Maximum [Member]
Convertible Preferred Stock, Shares Issued upon Conversion (in shares)					5,147,000
Jubilant [Member]
Stock Issued During Period, Shares, New Issues (in shares)							209,205
Proceeds from Issuance of Common Stock							$ 1,000,000
Jubilant [Member] | Private Placement [Member]
Sale of Stock, Commitment Amount							$ 1,000,000
Mastiff Group LLC [Member] | Private Placement [Member]
Stock Issued During Period, Shares, New Issues (in shares)						1,000,000
Proceeds from Issuance of Common Stock														$ 25,000
Sale of Stock, Commitment Amount						$ 25,000,000
Common Stock, Par or Stated Value Per Share (in dollars per share)						$ 0.001
Common Stock, Share Subscribed but Unissued, Subscriptions Receivable																				$ 4,975,000
John K. Scott, Jr. [Member] | Private Placement [Member]
Stock Issued During Period, Shares, New Issues (in shares)																			5,000
Sale of Stock, Commitment Amount						$ 25,000
John K. Scott, Jr. [Member] | Series E Preferred Stock [Member]
Stock Issued During Period, Shares, New Issues (in shares)			50,000
Stock Issued During Period, Value, New Issues			$ 5,000,000
Preferred Stock, Convertible, Shares Issuable (in shares)			2,173,913
Investor [Member]
Stock Issued During Period, Shares, New Issues (in shares)										4,000,000									4,020,588
Proceeds from Issuance of Common Stock										$ 3,400,000						$ 3,400,000

Note 3 - Revenue From Contrac_3

Note 3 - Revenue From Contracts With Customers (Details Textual) - USD ($)	11 Months Ended	12 Months Ended
	Dec. 13, 2021	Dec. 31, 2021	Dec. 31, 2020
Contract with Customer, Payment Term, Minimum (Day)	15 days
Contract with Customer, Payment Term, Maximum (Day)	90 days
Contract with Customer, Transaction Price of Royalties Using Expected Value Method		$ 0
Revenue from Contract with Customer, Including Assessed Tax		46,000	$ 119,000
Contract with Customer, Asset, Impairment Loss		0	0
Capitalized Contract Cost, Net, Total		0
Contract with Customer, Asset, after Allowance for Credit Loss, Total		1,000	59,000
Grant [Member]
Revenue Not from Contract with Customer		$ 88,000	$ 696,000
INDIA
Contract with Customer, Term of Contract (Year)		8 years
CHINA
Contract with Customer, Term of Contract (Year)		10 years

Note 3 - Revenue From Contrac_4

Note 3 - Revenue From Contracts With Customers - Disaggregation of Revenue (Details) - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Revenue from contract with customer	$ 46,000	$ 119,000
Royalty [Member]
Revenue from contract with customer	0	7,995
Diagnostics Segment [Member] | Royalty [Member]
Revenue from contract with customer	0	7,995
Diagnostics Segment [Member] | Royalty [Member] | Europe [Member]
Revenue from contract with customer	0	7,995
Diagnostics Segment [Member] | Expanded Tc99m Tilmanocept License Agreement [Member] | Europe [Member]
Revenue from contract with customer	$ 45,615	$ 110,730

Note 3 - Revenue From Contrac_5

Note 3 - Revenue From Contracts With Customers - Changes in Contract Liabilities (Details) - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Total deferred revenue, beginning of period	$ 700,000	$ 700,000
Revenue deferred related to sublicense	0	160,000
Refund of deferred revenue related to sublicense	0	(160,000)
Revenue recognized from satisfaction of performance obligations	0	0
Total deferred revenue, end of period	$ 700,000	$ 700,000

Note 4 - Stock-based Compensa_3

Note 4 - Stock-based Compensation (Details Textual) - USD ($)	Nov. 23, 2021	Dec. 31, 2021	Dec. 31, 2020
Share-based Payment Arrangement, Expense		$ 471,000	$ 231,000
Share-based Payment Arrangement, Expense, Tax Benefit		$ 0	$ 0
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number (in shares)		549,024
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value (in dollars per share)		$ 1.46	$ 1.36
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period (in shares)		4,000	0
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value		$ 2,500
Proceeds from Stock Options Exercised		4,240
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value		122,000	$ 0
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total		$ 320,000
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year)		1 year 9 months 18 days
Share-based Payment Arrangement, Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period (in shares)		4,000
Restricted Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period (in shares)		70,000	15,000
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value		$ 113,000	$ 17,000
Former Chief Executive Officer [Member]
Share-based Payment Arrangement, Expense	$ 243,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number (in shares)	69,918
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number (in shares)	333,332
Reversal of Allocated Share Based Compensation Expense	$ 503,000
Former Chief Executive Officer [Member] | Share-based Payment Arrangement, Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period (Year)	5 years
Former Chief Executive Officer [Member] | Restricted Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period (in shares)	33,333
Share-based Compensation Arrangement by Share-based Payment Award, Award Settlement Period (Day)	30 days
Director [Member] | Restricted Stock [Member] | Vesting As Scheduled [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period (in shares)		20,000	15,000
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value		$ 43,000	$ 17,000

Note 4 - Stock-based Compensa_4

Note 4 - Stock-based Compensation - Summary of Stock Option Activity (Details) - $ / shares	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Outstanding at beginning of period (in shares)	549,970
Outstanding at beginning of period, weighted average exercise price (in dollars per share)	$ 8.81
Granted (in shares)	459,500
Granted, weighted average exercise price (in dollars per share)	$ 1.94
Exercised (in shares)	(4,000)	0
Exercised, weighted average exercise price (in dollars per share)	$ 1.06
Canceled and forfeited (in shares)	(83,590)
Canceled and Forfeited, weighted average exercise price (in dollars per share)	$ 4.70
Expired (in shares)	(2,090)
Expired, weighted average exercise price (in dollars per share)	$ 61.75
Outstanding at end of period (in shares)	919,790	549,970
Outstanding at end of period, weighted average exercise price (in dollars per share)	$ 5.67	$ 8.81
Outstanding, weighted average remaining contractual life (Year)	6 years 6 months
Exercisable at end of period (in shares)	549,024
Exercisable at end of period, weighted average exercise price (in dollars per share)	$ 8.40
Exercisable, weighted average remaining contractual life (Year)	4 years 7 months 6 days

Note 4 - Stock-based Compensa_5

Note 4 - Stock-based Compensation - Summary of Unvested Restricted Stock (Details) - Restricted Stock [Member] - $ / shares	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Unvested at beginning of period (in shares)	60,000
Unvested at beginning of period, weighted average grant-date fair value (in dollars per share)	$ 2.90
Granted (in shares)	105,000
Granted, weighted average grant-date fair value (in dollars per share)	$ 1.48
Vested (in shares)	(70,000)	(15,000)
Vested, weighted average grant-date fair value (in dollars per share)	$ 2.81
Unvested at end of period (in shares)	95,000	60,000
Unvested at end of period, weighted average grant-date fair value (in dollars per share)	$ 1.40	$ 2.90

Note 5 - Loss Per Share (Detail

Note 5 - Loss Per Share (Details Textual) - shares	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Stock Options and Warrants [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount (in shares)	1,892,114	1,541,844
Restricted Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount (in shares)	95,000	60,000

Note 6 - Stock Subscriptions _3

Note 6 - Stock Subscriptions and Other Receivables and Concentrations of Credit Risk (Details Textual) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Accounts Receivable, Allowance for Credit Loss, Current	$ 0	$ 0
Customer Concentration Risk [Member] | Accounts and Other Receivables [Member] | An Investor [Member]
Concentration Risk, Percentage	0.00%	98.00%

Note 6 - Stock Subscriptions _4

Note 6 - Stock Subscriptions and Other Receivables and Concentrations of Credit Risk - Accounts and Other Receivables (Details) - USD ($)	Dec. 31, 2021	Dec. 31, 2020
Accounts and other receivables	$ 92,992	$ 2,987,319
Related Party Receivables [Member]
Accounts and other receivables	86,796	0
Stock Subscriptions [Member]
Accounts and other receivables	0	2,925,000
License Revenue Receivable [Member]
Accounts and other receivables	1,021	58,754
Grant Revenue Receivable [Member]
Accounts and other receivables	919	1,117
Other Accounts Receivable [Member]
Accounts and other receivables	$ 4,256	$ 2,448

Note 7 - Inventory (Details Tex

Note 7 - Inventory (Details Textual) - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Raw Materials [Member]
Inventory, Allocated to Manufacturing Process Development Expense	$ 28,000	$ 11,000
Finished Goods [Member]
Inventory, Allocated to Research and Development Expense	$ 0	$ 39,000

Note 7 - Inventory - Net Invent

Note 7 - Inventory - Net Inventory (Details) - USD ($)	Dec. 31, 2021	Dec. 31, 2020
Materials	$ 50,000	$ 77,750
Finished goods	101,155	92,048
Total inventory	$ 151,155	$ 169,798

Note 8 - Property and Equipme_3

Note 8 - Property and Equipment (Details Textual) - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Depreciation, Depletion and Amortization, Total	$ 36,803	$ 33,929

Note 8 - Property and Equipme_4

Note 8 - Property and Equipment - Summary of Major Classes of Property and Equipment (Details) - USD ($)		12 Months Ended
		Dec. 31, 2021	Dec. 31, 2020
Property and Equipment, Gross		$ 866,306	$ 845,379
Purchased Software [Member]
Property and Equipment, Useful Life (Year)		3 years
Property and Equipment, Gross		$ 320,435	320,435
Machinery and Equipment [Member]
Property and Equipment, Useful Life (Year)		5 years
Property and Equipment, Gross		$ 214,356	214,356
Other Machinery and Equipment [Member]
Property and Equipment, Gross		$ 304,492	297,315
Other Machinery and Equipment [Member] | Minimum [Member]
Property and Equipment, Useful Life (Year)		3 years
Other Machinery and Equipment [Member] | Maximum [Member]
Property and Equipment, Useful Life (Year)		5 years
Leasehold Improvements [Member]
Property and Equipment, Gross	[1]	$ 23,511	12,448
Furniture and Fixtures [Member]
Property and Equipment, Useful Life (Year)		7 years
Property and Equipment, Gross		$ 3,512	$ 825
[1]	We amortize leasehold improvements over the term of the lease, which in all cases is shorter than the estimated useful life of the asset.

Note 9 - Accounts Payable, Ac_3

Note 9 - Accounts Payable, Accrued Liabilities and Other (Details Textual) - USD ($)	Dec. 31, 2021	Dec. 31, 2020
Director Fees [Member] | Account Payable [Member]
Due to Related Parties, Current, Total	$ 57,000	$ 66,000
Termination Costs, Bonuses, and Benefits [Member] | Accrued Liabilities and Other [Member]
Due to Related Parties, Current, Total	$ 1,200,000	$ 755,000

Note 9 - Accounts Payable, Ac_4

Note 9 - Accounts Payable, Accrued Liabilities and Other - Accrued Liabilities and Other (Details) - USD ($)	Dec. 31, 2021	Dec. 31, 2020
Contracted services	$ 1,913,756	$ 1,725,866
Compensation	1,194,719	755,494
Other	40,865	31,634
Total accrued liabilities and other	$ 3,149,340	$ 2,512,994

Note 10 - Notes Payable (Detail

Note 10 - Notes Payable (Details Textual) - USD ($)	Feb. 23, 2021	May 18, 2020	Dec. 01, 2021	Nov. 30, 2020	Nov. 30, 2019	Dec. 31, 2021	Dec. 31, 2020	Nov. 30, 2021
Interest Expense, Debt, Total						$ 6,000	$ 6,000
Notes Payable, Current, Total						453,427	745,443
Proceeds from Notes Payable, Total						0	366,000
Gain (Loss) on Extinguishment of Debt, Total						366,000	0
Long-Term Debt, Maturity, Year One						453,000
Notes Payable Issued for Prepayment of Insurance Premiums [Member] | FIF [Member]
Debt Instrument, Face Amount					$ 349,000
Debt Instrument, Interest Rate, Stated Percentage					5.00%
Debt Instrument, Term (Month)					8 months
Debt Instrument, Periodic Payment, Total					$ 44,000
Interest Expense, Debt, Total							5,000
Notes Payable, Current, Total							379,000
Notes Payable Issued for Prepayment of Insurance Premiums [Member] | IPFS [Member]
Debt Instrument, Face Amount			$ 566,000	$ 442,000				$ 566,000
Debt Instrument, Interest Rate, Stated Percentage			4.36%	3.50%				4.36%
Debt Instrument, Term (Month)			5 months	7 months
Debt Instrument, Periodic Payment, Total			$ 114,000	$ 64,000
Interest Expense, Debt, Total						6,000	$ 1,000
Notes Payable, Current, Total						$ 453,000
Paycheck Protection Program CARES Act [Member]
Proceeds from Notes Payable, Total		$ 366,000
Gain (Loss) on Extinguishment of Debt, Total	$ 366,000

Note 11 - Leases (Details Textu

Note 11 - Leases (Details Textual)	1 Months Ended	12 Months Ended
	Jun. 30, 2017USD ($)	Dec. 31, 2021USD ($)ft²	Dec. 31, 2020USD ($)
Operating Lease, Payments		$ 344,000	$ 339,000
Selling, General and Administrative Expenses [Member]
Operating Lease, Expense		$ 172,000	$ 198,000
Office Space at 4995 Bradenton Avenue, Dublin Ohio [Member]
Area of Real Estate Property (Square Foot) | ft²		5,000
Operating Lease, Monthly Base Rent		$ 3,000
Office Space at 5600 Blazer Parkway, Dublin, Ohio [Member]
Area of Real Estate Property (Square Foot) | ft²		25,000
Operating Lease, Monthly Base Rent	$ 39,000	$ 27,000
Lessee, Operating Lease, Renewal Term (Year)		5 years
Office Equipment [Member]
Operating Lease, Monthly Base Rent		$ 100
Vehicle Lease [Member]
Operating Lease, Monthly Base Rent		$ 300

Note 11 - Leases - Maturity of

Note 11 - Leases - Maturity of Lease Liabilities (Details)	Dec. 31, 2021USD ($)
2022	$ 291,111
2023	19,699
2024	1,355
Total undiscounted operating lease payments	312,165
Less imputed interest	16,159
Present value of operating lease liabilities	$ 296,006

Note 11 - Leases - Balance Shee

Note 11 - Leases - Balance Sheet Classification (Details) - USD ($)	Dec. 31, 2021	Dec. 31, 2020
Current lease liabilities	$ 275,718	$ 294,951
Noncurrent lease liabilities	20,288	$ 296,006
Present value of operating lease liabilities	296,006
Other Current Liabilities [Member]
Current lease liabilities	275,718
Other Noncurrent Liabilities [Member]
Noncurrent lease liabilities	$ 20,288

Note 11 - Leases - Other Inform

Note 11 - Leases - Other Information (Details)	Dec. 31, 2021
Weighted-average remaining lease term for operating leases (years) (Year)	10 months 24 days
Weighted-average discount rate for operating leases	10.96%

Note 12 - Commitments and Con_2

Note 12 - Commitments and Contingencies (Details Textual) - USD ($)

Dec. 09, 2021

Nov. 21, 2021

May 27, 2021

Mar. 16, 2021

Nov. 27, 2019

Aug. 14, 2018

Apr. 09, 2018

Nov. 02, 2017

Mar. 03, 2017

Nov. 30, 2018

Apr. 30, 2018

Jun. 30, 2016

Dec. 31, 2021

Sep. 30, 2021

Dec. 31, 2020

Dec. 31, 2019

Aug. 31, 2018

Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest, Ending Balance

$ 624,743

$ 4,100,000

$ 2,046,907

$ (880,989)

Common Stock [Member]

Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest, Ending Balance

$ 221,277

$ 218,146

$ 210,232

Former Chief Executive Officer and President [Member]

Common Stock Shares Provided by Agreement (in shares)

1,175,000

Common Stock Shares Provided by Agreement, Escrow Period (Month)

18 months

Former Chief Executive Officer and President [Member] | Common Stock [Member]

Stock Issued During Period, Shares, New Issues (in shares)

925,000

Stock Issued During Period, Shares, New Issues Placed in Escrow (in shares)

250,000

250,000

Former Chief Executive Officer and President [Member] | MT [Member] | Common Stock [Member] | Dr. Michael Goldberg [Member]

Ownership Percentage

5.00%

CRG [Member]

Draws on Letter of Credit

$ 7,100,000

CRG Loan Agreement, Texas Case [Member]

Litigation Settlement, Attorneys’ Fees

$ 2,800,000

CRG Loan Agreement, Texas Case [Member] | Judicial Ruling [Member]

Loss Contingency, Damages Awarded, Value, Additional Amount

$ 7,000,000

Loss Contingency, Damages Awarded, Value, Amount not Taken into Consideration

$ 4,100,000

Ohio Court of Common Pleas [Member]

Litigation Settlement, Amount Awarded from Other Party

$ 4,300,000

Litigation Settlement, Reversal of Amount Awarded from Other Party

$ 4,300,000

Platinum-Montaur Life Sciences LLC Litigation [Member] | Pending Litigation [Member]

Loss Contingency, Damages Sought, Value

$ 1,900,000

New York Litigation Involving Former CEO and President [Member] | Judicial Ruling [Member]

Litigation Settlement, Amount Can Be Awarded to Other Party for Indemnification for Attorneys’ Fees

$ 14,955

Litigation Settlement, Amount Can Be Advanced to Other Party for Attorneys’ Fees Subject to Repayment

$ 1,237.50

Delaware Litigation Involving Former CEO and President [Member]

Litigation Settlement, Amount Awarded from Other Party

$ 66,796.33

CRG [Member] | Term Loan Agreement [Member] | CRG Loan Agreement, Texas Case [Member]

Overpayment of Debt

$ 4,200,000

CRG [Member] | Term Loan Agreement [Member] | CRG Loan Agreement, Texas Case [Member] | Judicial Ruling [Member]

Repayments of Debt

59,000,000

CRG [Member] | Term Loan Agreement [Member] | Maximum [Member]

Debt Instrument, Agreed-upon Final Payoff Amount

$ 66,000,000

Note 13 - Equity Instruments (D

Note 13 - Equity Instruments (Details Textual) - USD ($)		Jul. 08, 2021	Mar. 02, 2021	Aug. 31, 2020	Aug. 30, 2020	Aug. 09, 2020	May 06, 2020	Feb. 29, 2020	Jan. 31, 2020	Dec. 31, 2019	Nov. 30, 2018	Jan. 31, 2020	Mar. 25, 2021	Sep. 30, 2020	Sep. 30, 2020	Jul. 07, 2021	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2021	Jun. 30, 2021	Mar. 31, 2020
Proceeds from Issuance of Common Stock																	$ 4,346	$ 4,442,560
Common Stock, Share Subscribed but Unissued, Subscriptions Receivable																	0	4,975,000	$ 0
Proceeds from Issuance of Preferred Stock and Preference Stock																	$ 12,682,700	$ 5,975,000
Stock Issued During Period, Shares, Employee Benefit Plan (in shares)																	30,018	32,651
Stock Issued During Period, Value, Employee Benefit Plan																	$ 76,846	$ 39,834
Stock Issued During Period, Value, Issued for Employee Bonuses																		$ 171,522
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)																	972,324		972,324
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)	[1]																$ 17.97		$ 17.97
Common Stock, Capital Shares Reserved for Future Issuance (in shares)																	1,892,114		1,892,114
Director [Member]
Common Stock, Capital Shares Reserved for Future Issuance (in shares)																	49,242		49,242
Common Stock [Member]
Stock Issued During Period, Shares, Employee Benefit Plan (in shares)																	30,018	32,651
Stock Issued During Period, Value, Employee Benefit Plan																	$ 30	$ 33
Stock Issued During Period, Shares, Issued for Employee Bonuses (in shares)																		94,159
Stock Issued During Period, Value, Issued for Employee Bonuses																		$ 94
Common Stock [Member] | Former Chief Executive Officer and President [Member]
Stock Issued During Period, Shares, New Issues (in shares)											925,000
Stock Issued During Period, Shares, New Issues Placed in Escrow (in shares)											250,000						250,000
Common Stock [Member] | Macrophage Therapeutics [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)																					300
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)																					$ 2,000
Maximum [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)																	$ 49.80		$ 49.80
Warrants and Rights Outstanding, Term (Year)																	13 years 7 months 6 days		13 years 7 months 6 days
Minimum [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)																	$ 0.20		$ 0.20
Warrants and Rights Outstanding, Term (Year)																	2 months 12 days		2 months 12 days
Weighted Average [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)																	$ 17.97		$ 17.97
Conversion from Series C Preferred Stock To Common Stock [Member]
Conversion of Stock, Shares Converted (in shares)																		420,000
Conversion of Stock, Shares Issued (in shares)																		1,425,076
Conversion from Series D Preferred Stock To Common Stock [Member]
Stock Issued During Period, Shares, New Issues (in shares)																72,500
Conversion of Stock, Shares Converted (in shares)													29,250				54,750	17,750
Conversion of Stock, Shares Issued (in shares)													1,375,089				2,951,509	827,280	3,778,789
Common Stock, Capital Shares Reserved for Future Issuance (in shares)																	1,368,211		1,368,211
Conversion from Series E Preferred Stock To Common Stock [Member
Common Stock, Capital Shares Reserved for Future Issuance (in shares)																	2,173,913		2,173,913
Series C Preferred Stock [Member]
Stock Issued During Period, Value, New Issues																		$ 4,163,178
Preferred Stock, Deemed Dividend																		$ 467,000
Conversion of Stock, Shares Converted (in shares)															420,000			420,000
Series C Preferred Stock [Member] | Common Stock [Member]
Stock Issued During Period, Shares, New Issues (in shares)																		0
Stock Issued During Period, Value, New Issues																		$ 0
Series D Preferred Stock [Member]
Stock Issued During Period, Value, New Issues																	$ 2,550,001	132,107
Preferred Stock, Deemed Dividend																		$ 197,000
Conversion of Stock, Shares Converted (in shares)																		17,750
Preferred Stock, Shares Subscribed but Unissued, Subscriptions Receivable																	$ 0	$ 10,300,000	$ 0
Preferred Stock, Shares Outstanding, Ending Balance (in shares)																	22,077	0	22,077
Series D Preferred Stock [Member] | Common Stock [Member]
Stock Issued During Period, Shares, New Issues (in shares)																		0
Stock Issued During Period, Value, New Issues																		$ 0
Series D Preferred Stock [Member] | Stock Subscriptions and Other Receivables [Member]
Stock Subscriptions Receivable																		$ 2,900,000
Series E Preferred Stock [Member]
Stock Issued During Period, Value, New Issues																	$ 4,930,038
Preferred Stock, Shares Outstanding, Ending Balance (in shares)																	50,000	0	50,000
Preferred Stock, Convertible, Conversion Price (in dollars per share)			$ 2.30
Preferred Stock, Redemption Price Per Share (in dollars per share)			$ 110
Keystone Capital Partners, LLC [Member] | Series C Preferred Stock [Member]
Stock Issued During Period, Shares, New Issues (in shares)							420,000											420,000
Proceeds from Issuance of Common Stock																		$ 4.2
Stock Issued During Period, Value, New Issues							$ 4,200,000
Convertible Preferred Stock, Discount to Market Rate							10.00%
Convertible Preferred Stock, Maximum Allowed Percentage of Common Stock Outstanding Used in Conversion Shares							19.99%
Proceeds from Issuance of Preferred Stock and Preference Stock														$ 4,200,000
Keystone Capital Partners, LLC [Member] | Series D Preferred Stock [Member]
Stock Issued During Period, Shares, New Issues (in shares)		22,077		150,000									29,250			72,500	76,827	17,750
Stock Issued During Period, Value, New Issues		$ 2,200,000		$ 15,000,000												$ 7,250,000	$ 7,700,000
Convertible Preferred Stock, Discount to Market Rate				10.00%
Convertible Preferred Stock, Maximum Allowed Percentage of Common Stock Outstanding Used in Conversion Shares				19.99%
Preferred Stock, Deemed Dividend																		$ 197,000
Stock Issued During Period, Value, Other				$ 15
Convertible Preferred Stock, Shares Issued upon Conversion (in shares)				5,147,000
Proceeds from Issuance of Preferred Stock and Preference Stock													$ 2,900,000					$ 1,800,000
Preferred Stock, Shares Outstanding, Ending Balance (in shares)																	22,077		22,077
Keystone Capital Partners, LLC [Member] | Series D Preferred Stock [Member] | Maximum [Member]
Convertible Preferred Stock, Shares Issued upon Conversion (in shares)				5,147,000
Jubilant [Member]
Stock Issued During Period, Shares, New Issues (in shares)						209,205
Proceeds from Issuance of Common Stock						$ 1,000,000
John K. Scott, Jr. [Member] | Series E Preferred Stock [Member]
Stock Issued During Period, Shares, New Issues (in shares)			50,000
Stock Issued During Period, Value, New Issues			$ 5,000,000
Percentage of Securities Allowed to be Purchased in Third-Party Offering, Maximum			33.33%
Investor [Member]
Stock Issued During Period, Shares, New Issues (in shares)								4,000,000										4,020,588
Proceeds from Issuance of Common Stock								$ 3,400,000							$ 3,400,000
Employees [Member] | Common Stock [Member]
Stock Issued During Period, Shares, Issued for Employee Bonuses (in shares)																		94,159
Stock Issued During Period, Value, Issued for Employee Bonuses																	$ 0	$ 172,000
Private Placement [Member]
Stock Issued During Period, Shares, New Issues (in shares)												2,100,000
Proceeds from Issuance of Common Stock									$ 812,000	$ 1,100,000		$ 1,900,000
Stock Issued During Period, Value, New Issues																		$ 2,059
Private Placement [Member] | Common Stock [Member]
Stock Issued During Period, Shares, New Issues (in shares)																		3,280,691
Stock Issued During Period, Value, New Issues																		$ 3,281
Private Placement [Member] | Jubilant [Member]
Sale of Stock, Commitment Amount						$ 1,000,000
Private Placement [Member] | Mastiff Group LLC [Member]
Stock Issued During Period, Shares, New Issues (in shares)					1,000,000
Proceeds from Issuance of Common Stock													$ 25,000
Sale of Stock, Commitment Amount					$ 25,000,000
Shares Issued, Price Per Share (in dollars per share)					$ 5
Common Stock, Share Subscribed but Unissued, Subscriptions Receivable																				$ 4,975,000
Private Placement [Member] | Mastiff Group LLC [Member] | Stock Subscriptions and Other Receivables [Member]
Common Stock, Share Subscribed but Unissued, Subscriptions Receivable																		$ 4,975,000		$ 4,975,000
Private Placement [Member] | Mastiff Group LLC [Member] | Maximum [Member]
Shares Issued, Price Per Share (in dollars per share)					$ 5.75
Private Placement [Member] | John K. Scott, Jr. [Member]
Stock Issued During Period, Shares, New Issues (in shares)																		5,000
Sale of Stock, Commitment Amount					$ 25,000
[1]	Weighted average exercise price.

Note 13 - Equity Instruments -

Note 13 - Equity Instruments - Outstanding Warrants (Details)	Dec. 31, 2021$ / sharesshares
Exercise Price (in dollars per share) | $ / shares	$ 17.97	[1]
Number of Warrants (in shares) | shares	972,324
Series HH Warrants [Member]
Exercise Price (in dollars per share) | $ / shares	$ 49.80
Number of Warrants (in shares) | shares	15,060
Series LL Warrants [Member]
Exercise Price (in dollars per share) | $ / shares	$ 0.20
Number of Warrants (in shares) | shares	218,264
Series NN Warrants [Member]
Exercise Price (in dollars per share) | $ / shares	$ 30
Number of Warrants (in shares) | shares	550,000
Series OO Warrants [Member]
Exercise Price (in dollars per share) | $ / shares	$ 0.9375
Number of Warrants (in shares) | shares	189,000
[1]	Weighted average exercise price.

Note 14- Income Taxes (Details

Note 14- Income Taxes (Details Textual) - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2018	Jun. 30, 2020
Deferred Tax Assets, Gross, Total	$ 48,499,905	$ 45,823,037
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent	21.00%	21.00%
Revaluation of Deferred Tax Asset, Decrease			$ (26,400,000)
Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount			$ 26,400,000
Domestic Tax Authority [Member] | Internal Revenue Service (IRS) [Member]
Operating Loss Carryforwards, Total	$ 164,103,350	$ 153,300,000
Operating Loss Carryforwards Stock-based Compensation	14,900,000
State and Local Jurisdiction [Member]
Operating Loss Carryforwards, Total	20,100,000	20,100,000
Alternative Minimum Tax [Member]
Tax Credit Carryforward, Amount				$ 621,000
Research Tax Credit Carryforward [Member] | Domestic Tax Authority [Member] | Internal Revenue Service (IRS) [Member]
Tax Credit Carryforward, Amount	9,112,411	8,900,000
Tax Credit Carryforward, Amount Expired During Period	$ 0	$ 72,000

Note 14 - Income Taxes - Compon

Note 14 - Income Taxes - Components of Deferred Tax Assets (Details) - USD ($)	Dec. 31, 2021	Dec. 31, 2020
Deferred tax assets:
Net operating loss carryforwards	$ 36,793,074	$ 34,365,098
R&D credit carryforwards	9,501,299	9,301,709
Stock compensation	481,098	419,654
Intangibles	567,213	616,926
Disallowed interest expense	851,247	852,338
Temporary differences	305,974	267,312
Deferred tax assets before valuation allowance	48,499,905	45,823,037
Valuation allowance	(48,499,905)	(45,823,037)
Net deferred tax assets	$ 0	$ 0

Note 14 - Income Taxes - Net Op

Note 14 - Income Taxes - Net Operating Loss and Credit Carryforwards (Details) - Domestic Tax Authority [Member] - Internal Revenue Service (IRS) [Member] - USD ($)	Dec. 31, 2021	Dec. 31, 2020
U.S. Net Operating Loss Carryforwards	$ 164,103,350	$ 153,300,000
Research Tax Credit Carryforward [Member]
U.S. R&D Credit Carryforwards	9,112,411	$ 8,900,000
Tax Year 2001 [Member] | Research Tax Credit Carryforward [Member]
U.S. R&D Credit Carryforwards	39,128
Tax Year 2002 [Member] | Research Tax Credit Carryforward [Member]
U.S. R&D Credit Carryforwards	5,350
Tax Year 2003 [Member] | Research Tax Credit Carryforward [Member]
U.S. R&D Credit Carryforwards	2,905
Tax Year 2004 [Member] | Research Tax Credit Carryforward [Member]
U.S. R&D Credit Carryforwards	22,861
Tax Year 2005 [Member] | Research Tax Credit Carryforward [Member]
U.S. R&D Credit Carryforwards	218,332
Tax Year 2006 [Member] | Research Tax Credit Carryforward [Member]
U.S. R&D Credit Carryforwards	365,541
Tax Year 2007 [Member] | Research Tax Credit Carryforward [Member]
U.S. R&D Credit Carryforwards	342,898
Tax Year 2008 [Member] | Research Tax Credit Carryforward [Member]
U.S. R&D Credit Carryforwards	531,539
Tax Year 2009 [Member] | Research Tax Credit Carryforward [Member]
U.S. R&D Credit Carryforwards	596,843
Tax Year 2010 [Member] | Research Tax Credit Carryforward [Member]
U.S. R&D Credit Carryforwards	1,094,449
Tax Year 2011 [Member] | Research Tax Credit Carryforward [Member]
U.S. R&D Credit Carryforwards	1,950,744
Tax Year 2012 [Member]
U.S. Net Operating Loss Carryforwards	18,898,490
Tax Year 2012 [Member] | Research Tax Credit Carryforward [Member]
U.S. R&D Credit Carryforwards	468,008
Tax Year 2013 [Member]
U.S. Net Operating Loss Carryforwards	37,450,522
Tax Year 2013 [Member] | Research Tax Credit Carryforward [Member]
U.S. R&D Credit Carryforwards	681,772
Tax Year 2014 [Member]
U.S. Net Operating Loss Carryforwards	34,088,874
Tax Year 2014 [Member] | Research Tax Credit Carryforward [Member]
U.S. R&D Credit Carryforwards	816,116
Tax Year 2015 [Member]
U.S. Net Operating Loss Carryforwards	25,073,846
Tax Year 2015 [Member] | Research Tax Credit Carryforward [Member]
U.S. R&D Credit Carryforwards	492,732
Tax Year 2016 [Member]
U.S. Net Operating Loss Carryforwards	15,581,209
Tax Year 2016 [Member] | Research Tax Credit Carryforward [Member]
U.S. R&D Credit Carryforwards	262,257
Tax Year 2017 [Member] | Research Tax Credit Carryforward [Member]
U.S. R&D Credit Carryforwards	387,892
Tax Year 2018 [Member] | Research Tax Credit Carryforward [Member]
U.S. R&D Credit Carryforwards	197,547
Tax Year 2019 [Member]
U.S. Net Operating Loss Carryforwards	11,245,808
Tax Year 2019 [Member] | Research Tax Credit Carryforward [Member]
U.S. R&D Credit Carryforwards	213,065
Tax Year 2020 [Member]
U.S. Net Operating Loss Carryforwards	11,018,478
Tax Year 2020 [Member] | Research Tax Credit Carryforward [Member]
U.S. R&D Credit Carryforwards	222,842
Tax Year 2021 [Member]
U.S. R&D Credit Carryforwards	238,717
U.S. Net Operating Loss Carryforwards	$ 10,746,123

Note 14 - Income Taxes - Reconc

Note 14 - Income Taxes - Reconciliations Between the Statutory Federal Income Tax Rate and the Effective Tax Rate (Details) - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Benefit at statutory rate, amount	$ (2,460,126)	$ (2,390,972)
Benefit at statutory rate, percent	(21.00%)	(21.00%)
Adjustments to valuation allowance, amount	$ 2,676,868	$ 2,521,625
Adjustments to valuation allowance, percent	22.90%	22.10%
Adjustments to R&D credit carryforwards, amount	$ (199,589)	$ (151,129)
Adjustments to R&D credit carryforwards, percent	(1.70%)	(1.30%)
Permanent items and other, amount	$ (1,110)	$ 20,476
Permanent items and other, percent	(0.10%)	0.20%
Provision (benefit) per financial statements	$ 16,043	$ 0

Note 15- Segments (Details Text

Note 15- Segments (Details Textual)		12 Months Ended
		Dec. 31, 2021USD ($)	Dec. 31, 2020USD ($)
Revenues, Total		$ 531,513	$ 915,013
Number of Primary Types of Products Sold		2
Depreciation, Depletion and Amortization, Nonproduction, Total	[1]	$ 76,954	70,393
Selling, General and Administrative Expenses [Member]
Depreciation, Depletion and Amortization, Nonproduction, Total		76,954	$ 70,393
Intersegment Eliminations [Member]
Revenues, Total		$ 0
[1]	Depreciation and amortization are reflected in selling, general and administrative expenses ($76,954 and $70,393 for the years ended December 31, 2021 and 2020, respectively).

Note 15 - Segments - Segment In

Note 15 - Segments - Segment Information (Details) - USD ($)		12 Months Ended
		Dec. 31, 2021	Dec. 31, 2020
Revenue from contract with customer		$ 46,000	$ 119,000
Grant and other revenue		485,898	796,288
Revenues, Total		531,513	915,013
Research and development expenses, excluding depreciation and amortization		5,141,910	4,930,187
Selling, general and administrative expenses, excluding depreciation and amortization	[1]	7,373,061	6,624,566
Depreciation, Depletion and Amortization, Nonproduction, Total	[2]	76,954	70,393
Loss from operations	[3]	(12,060,412)	(10,711,181)
Other income (4)	[4]	345,524	(10,510)
Provision for income taxes		(16,043)	0
Net loss		(11,730,931)	(10,721,691)
Total assets, net of depreciation and amortization		6,644,833	7,758,018
Capital expenditures		25,218	135,881
Cost of revenue		0	1,048
Research and Development Expense, Total		5,141,910	4,930,187
UNITED STATES
Total assets, net of depreciation and amortization		6,433,962	7,555,227
Non-US [Member]
Total assets, net of depreciation and amortization		210,871	202,791
Royalty [Member]
Revenue from contract with customer		0	7,995
License [Member]
Revenue from contract with customer		45,615	110,730
Diagnostics Segment [Member]
Grant and other revenue		485,898	482,221
Revenues, Total		531,513	600,946
Research and development expenses, excluding depreciation and amortization		4,488,177	4,593,459
Selling, general and administrative expenses, excluding depreciation and amortization	[1]	0	299,959
Depreciation, Depletion and Amortization, Nonproduction, Total	[2]	24,162	10,068
Loss from operations	[3]	(3,980,826)	(4,303,588)
Other income (4)	[4]	0	0
Provision for income taxes		(5,452)
Net loss		(3,986,278)	(4,303,588)
Capital expenditures		0	120,810
Cost of revenue			1,048
Research and Development Expense, Total		4,488,177	4,593,459
Diagnostics Segment [Member] | UNITED STATES
Total assets, net of depreciation and amortization		107,931	139,121
Diagnostics Segment [Member] | Non-US [Member]
Total assets, net of depreciation and amortization		210,281	202,791
Diagnostics Segment [Member] | Royalty [Member]
Revenue from contract with customer		0	7,995
Diagnostics Segment [Member] | License [Member]
Revenue from contract with customer		45,615	110,730
Therapeutics Segment [Member]
Grant and other revenue		0	314,067
Revenues, Total		0	314,067
Research and development expenses, excluding depreciation and amortization		653,733	336,728
Selling, general and administrative expenses, excluding depreciation and amortization	[1]	4,438	800
Depreciation, Depletion and Amortization, Nonproduction, Total	[2]	0	0
Loss from operations	[3]	(658,171)	(23,461)
Other income (4)	[4]	0	0
Provision for income taxes		(901)
Net loss		(659,072)	(23,461)
Capital expenditures		0	0
Cost of revenue			0
Research and Development Expense, Total		653,733	336,728
Therapeutics Segment [Member] | UNITED STATES
Total assets, net of depreciation and amortization		0	0
Therapeutics Segment [Member] | Non-US [Member]
Total assets, net of depreciation and amortization		0	0
Therapeutics Segment [Member] | Royalty [Member]
Revenue from contract with customer		0	0
Therapeutics Segment [Member] | License [Member]
Revenue from contract with customer		0	0
Corporate Segment [Member]
Grant and other revenue		0	0
Revenues, Total		0	0
Research and development expenses, excluding depreciation and amortization		0	0
Selling, general and administrative expenses, excluding depreciation and amortization	[1]	7,368,623	6,323,807
Depreciation, Depletion and Amortization, Nonproduction, Total	[2]	52,792	60,325
Loss from operations	[3]	(7,421,415)	(6,384,132)
Other income (4)	[4]	345,524	(10,510)
Provision for income taxes		(9,690)
Net loss		(7,085,581)	(6,394,642)
Capital expenditures		25,218	15,071
Cost of revenue			0
Research and Development Expense, Total		0	0
Corporate Segment [Member] | UNITED STATES
Total assets, net of depreciation and amortization		6,326,031	7,416,106
Corporate Segment [Member] | Non-US [Member]
Total assets, net of depreciation and amortization		590	0
Corporate Segment [Member] | Royalty [Member]
Revenue from contract with customer		0	0
Corporate Segment [Member] | License [Member]
Revenue from contract with customer		$ 0	$ 0
[1]	General and administrative expenses, excluding depreciation and amortization, represent costs that relate to the general administration of the Company and as such are not currently allocated to our individual reportable segments, other than those expenses directly incurred by Navidea Europe, Navidea UK and MT.
[2]	Depreciation and amortization are reflected in selling, general and administrative expenses ($76,954 and $70,393 for the years ended December 31, 2021 and 2020, respectively).
[3]	Loss from operations does not reflect the allocation of certain selling, general and administrative expenses, excluding depreciation and amortization, to our individual reportable segments, other than those expenses directly incurred by Navidea Europe, Navidea UK and MT.
[4]	Amounts consist primarily of gain on extinguishment of debt, interest income and interest expense, which are not currently allocated to our individual reportable segments.

Note 16 - Material Agreements (

Note 16 - Material Agreements (Details Textual) - USD ($)	Oct. 24, 2022	Nov. 23, 2021	Jul. 31, 2014	Jan. 31, 2002	Dec. 31, 2021	Dec. 31, 2020	Oct. 24, 2021
Research and Development Expense, Total					$ 5,141,910	$ 4,930,187
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number (in shares)					549,024
Restricted Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period (in shares)					70,000	15,000
Former Chief Executive Officer [Member]
Employment Agreement, Annual Base Salary							$ 490,000
Separation Agreement, Salary Continuation		$ 490,000
Separation Agreement, Salary Continuation, Term (Month)		12 months
Separation Agreement, Salary Continuation, Percentage of Base Salary		100.00%
Separation Agreement, Reimbursement for Attorney Fees		$ 24,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number (in shares)		69,918
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number (in shares)		333,332
Separation Agreement, Reimbursed Expenses, Per Hour		250
Separation Agreement, Payment for Capital Raised, Percent		1.00%
Separation Agreement, Payment for Capital Raised, Term (Month)		22 months
Former Chief Executive Officer [Member] | Restricted Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period (in shares)		33,333
Former Chief Executive Officer [Member] | Share-based Payment Arrangement, Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period (Year)		5 years
Former Chief Executive Officer [Member] | Forecast [Member]
Separation Agreement, Salary Continuation, Term (Month)	10 months
Separation Agreement, Salary Continuation, Percentage of Base Salary	50.00%
Tc99m Tilmanocept License Agreement [Member]
License Issue Fee				$ 25,000
License Maintenance Fee				25,000
Minimum Annual Royalty				$ 25,000
Expanded Tc99m Tilmanocept License Agreement [Member] | Outside the Territory [Member] | License [Member]
Cost of Goods and Services Sold, Total					$ 4,000	$ 1,000
Amended and Restated Tilmanocept License Agreement [Member]
Research and Development Expense, Total					21,000	34,000
Tilmanocept License Agreement [Member]
License Issue Fee			$ 25,000
License Maintenance Fee			25,000
Minimum Annual Royalty			$ 25,000
Research and Development Expense, Total					$ 25,000	$ 275,000

Note 17 - Employee Benefit Pl_2

Note 17 - Employee Benefit Plan (Details Textual) - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Defined Contribution Plan, Employer Matching Contribution, Percent of Match	100.00%	40.00%
Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay	6.00%	5.00%
Defined Contribution Plan, Cost	$ 148,000	$ 49,000

Note 18 - Supplemental Disclo_2

Note 18 - Supplemental Disclosure for Statements of Cash Flows (Details Textual) - USD ($)	1 Months Ended	3 Months Ended	9 Months Ended	12 Months Ended		16 Months Ended
	Feb. 29, 2020	Mar. 25, 2021	Sep. 30, 2020	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2021	Dec. 01, 2021	Nov. 30, 2021	Nov. 30, 2020
Interest Paid, Excluding Capitalized Interest, Operating Activities				$ 9,000	$ 6,000
Stock Issued During Period, Value, Issued for Employee Bonuses					$ 171,522
Stock Issued During Period, Shares, Employee Benefit Plan (in shares)				30,018	32,651
Stock Issued During Period, Value, Employee Benefit Plan				$ 76,846	$ 39,834
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)				972,324		972,324
Conversion from Series C Preferred Stock To Common Stock [Member]
Conversion of Stock, Shares Converted (in shares)					420,000
Conversion of Stock, Shares Issued (in shares)					1,425,076
Conversion from Series D Preferred Stock To Common Stock [Member]
Conversion of Stock, Shares Converted (in shares)		29,250		54,750	17,750
Conversion of Stock, Shares Issued (in shares)		1,375,089		2,951,509	827,280	3,778,789
Series C Preferred Stock [Member]
Preferred Stock, Deemed Dividend					$ 467,000
Conversion of Stock, Shares Converted (in shares)			420,000		420,000
Series D Preferred Stock [Member]
Preferred Stock, Deemed Dividend					$ 197,000
Conversion of Stock, Shares Converted (in shares)					17,750
Series OO Warrants [Member]
Class of Warrant or Right, Exercised During Period (in shares)					411,000
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)					300,595
Notes Payable Issued for Prepayment of Insurance Premiums [Member] | IPFS [Member]
Debt Instrument, Face Amount							$ 566,000	$ 566,000	$ 442,000
Debt Instrument, Interest Rate, Stated Percentage							4.36%	4.36%	3.50%
Common Shares Issued in Lieu of 2019 Cash Bonus [Member]
Stock Issued During Period, Shares, Issued for Employee Bonuses (in shares)					94,159
Stock Issued During Period, Value, Issued for Employee Bonuses					$ 172,000
Office Lease [Member]
Right-of-Use Asset Obtained in Exchange for Operating Lease Liability	$ 100,432